Endocrinol Metab Clin N Am
31 (2002) 1083–1138

ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA

Subject Index to Volume 31

Volume 31

March	ENDOCRINE MANIFESTATIONS OF SYSTEMIC DISEASE, pages 1–260
June	AUTOIMMUNE POLYENDOCRINE SYNDROMES, pages 261–520
September	EVIDENCE-BASED ENDOCRINOLOGY, pages 521–854
December	NEPHROLITHIASIS, pages 855–1138

Note: Page numbers of article titles are in **boldface** type.

A

Abdominal radiography, for nephrolithiasis analysis, 916, 1033–1034

Absolute risk, of diabetes mellitus complications, 546
of postmenopausal osteoporosis, 666, 675

Absorptive hypercalciuria (AH), nephrolithiasis with, calcium intake and, 1021
genetics of, 877–879
mechanisms of, 873–874

Acetazolamide, for uric acid nephrolithiasis, 909

Acetohydroxamic acid, for cystinuria, 1060
for struvite calculi, 970–971

Acetylcholine receptor, in autoimmunity, 417

Acid load test, for nephrolithiasis, 907, 1042

Acid-base imbalance, in Cushing's syndrome, 200, 202

Acid-base parameters, effect on citrate metabolism, 888
pathogenic, 889–891
in uric acid nephrolithiasis, 905–908
bowel disease and, 981, 994–995
therapeutic interventions, 909

Acidification, of urine, for cystinuria, 1061
for struvite calculi, 971

Aciduria, orotic, childhood nephrolithiasis and, 1009

ACP Journal Club, as evidence-based medicine resource, 529–530
problem-based example of, 533

Acquired absorptive hypercalciuria, nephrolithiasis with, 875–876

Acquired immunity, antigen recognition with, B-lymphocytes and, 262–264
T-lymphocytes and, 264–265
features of, 261–262
helper T-cell subsets in, 265, 277
in neonates, 285–286
lymphocyte activation in, 266–267, 461

Actigraphy, of sleep disorders, 22

Acute phase, of chronic diseases, glucocorticoid therapy for, 752–754, 757
withdrawal analysis for, 759, 764–771.
See also *Glucocorticoid withdrawal schemes*.

Addison's disease, autoimmune polyendocrine syndrome type I and, 314
autoimmune polyendocrine syndrome type II and, ACTH-receptor antibodies and, 379
adrenal cortex autoantibodies and, 369–372, 378
animal models of, 432–434
clinical applications of, 382–384
clinical spectrum of, 357, 373–376
diagnostic approach to, 343–345
genetics of, 355–361
organ-specific autoantibodies and, 381–382
steroid-producing cell autoantibodies and, 376–378

0889-8529/02/$ - see front matter © 2002, Elsevier Science (USA). All rights reserved.
PII: S0889-8529(02)00076-2

Addison's disease (*continued*)
fatigue and, 25–26
type 1A diabetes mellitus-associated autoimmunity and, 397–399

Adenine phosphoribosyl transferase (APRT), childhood nephrolithiasis and, 1009

Adenoma(s), ectopic pituitary gland, 199, 214

Adherence, by physicians, to evidence-based medicine guidelines, 805–807

Adoption, by physicians, as evidence-based medicine factor, 806–807

Adrenal cell autoantibodies (ACA), in autoimmune polyendocrine syndrome type II, 370–376
clinical applications of, 382–384
diagnostic approach to, 343–344
diagnostic sensitivity and specificity of, 370–373
preclinical adrenal insufficiency and, 373–376

Adrenal gland, cortex growth, with proopiomelanocortin hypersecretion, 196–197
insufficiency of. See *Adrenal insufficiency*.
stress response and, 80–81, 83
medullary cells and, 82–83

Adrenal hypoplasia congenita (AHC), autoimmune polyendocrine syndrome type II and, 372

Adrenal insufficiency, autoimmune polyendocrine syndrome type II and, 370
animal models of, 432–434
clinical aspects of, 340–341
diagnostic approach to, 342–347
diagnostic sensitivities with, 370–373
preclinical, 373–376
treatment of, 348–350
autoimmune polyglandular syndrome type I and, 295, 298, 304
diagnostic approach to, 306, 308
prognosis of, 316–317
treatment of, 310, 312, 314
fatigue and, 25–26
primary. See *Addison's disease*.
with glucocorticoid therapy, 752–753

Adrenaline. See *Epinephrine*.

Adrenalitis, autoimmune polyglandular syndrome type II and, 340, 342

β-Adrenergic receptors, epinephrine actions on, 84–85, 87–88
in cardiac arrest, 92–94, 96
polymorphisms of, in type-2 diabetes mellitus, 559–561

α-Adrenergic receptors, epinephrine actions on, 84–85
in cardiac arrest, 92–93

Adrenocorticotropic hormone (ACTH), ectopic syndromes of, 193, 197–199
fibromyalgia and, 8–9
hypercortisolism dependency and, 196–197, 207–209
insomnia and, 21–24
major depression and, amenorrhea similarities with, 67–68
atypical correlations, 53–55
melancholic correlations, 48–51
neuroendocrine-immune regulatory loop and, 2–3
animal models of, 4–5, 8
obesity effects on, 179–180
Cushing's syndrome versus, 181
POMC gene transcription and, 193, 195
releasing hormone for. See *Corticotropin-releasing hormone (CRH)*.
resistance syndrome, autoimmune polyendocrine syndrome type II and, 372, 376
rheumatoid arthritis and, 5–6
sleep effects of, 17–19, 25
steroidogenesis function of, 196
stimulation test, for autoimmune polyendocrine syndrome type II, 347, 374–375, 379, 384
for autoimmune polyglandular syndrome type I, 308
stress response and, 41, 47–50, 80
systemic lupus erythematosus and, 7

Adrenoleukodystrophy (ALD), autoimmune polyendocrine syndrome type II and, 370, 372

Aerobic exercise, growth hormone effects of, 178

Affective disorder(s), atypical depression as, 53–55
unipolar versus bipolar, 38

Afferent pathways, of epinephrine, in acute severe stress, 81–82

African trypanosomiasis, sleep disorders in, 26

Age, sleep cycles and, 15–17
cytokines in, 28
hypothalmic-pituitary-adrenal axis in, 20

Agency for Healthcare Research and Quality (AHRQ), Evidence-Based Practice Centers of, 795, 802, 809

Agreement, by physicians, as evidence-based medicine factor, 806

AIRE gene, autoimmune polyglandular syndrome type I and, 295, 306, 322
animal models of, 431–432
future applications of, 335–336
mutations of, 326–329, 333–335
detection of message of, 322–323
detection of protein of, 323–325, 425
functional incompetence of, 333–335
functional studies on, 333
homogeneously staining region of, 329
mutations of, animal models of, 431–432
functional incompetence of, 333–335
in autoimmune polyglandular syndrome type 1, 326–329
nuclear localization signal of, 332–333
nuclear receptor-binding motifs of, 332–333
PHD domains of, 330–332
population analysis and functions of, **321–338**
proline-rich region of, 332
regulation of expression of, 326, 336
SAND domain of, 329–331
structure and function of, 329–333
subcellular localization of, 325–326
tissue distribution of, 322–325

AIRE message, detection of, 322–323

AIRE protein, detection of, 323–325

Alanine-glyoxylate amino-transferase (AGT), in primary hyperoxaluria, 932–937, 939
childhood, 1006

Albumin-to-creatinine ratio, in diabetes mellitus complications, 543–1267

Albuminuria. See *Microalbuminuria.*

Aldosterone-to-renin ratio (ARR), as screen test for primary aldosteronism, **619–632**
current status of, 619–620
systematic review of, 619–629
discussion on, 623, 627–629
materials and methods for, 619–621
results of, 621–627

Aldosteronism. See *Primary aldosteronism.*

Alendronate, in postmenopausal osteoporosis trials, 661–676

Alkalinization, of urine, for cystinuria, 966
for uric acid nephrolithiasis, 909
in children, 1012
with small bowel disease, 982–983

Alleles. See *Genetics.*

Allopurinol, for hyperuricosuria, 1057–1058
for hyperuricosuric calcium nephrolithiasis, 921–922
uric acid nephrolithiasis from, 909

Alopecia, autoimmune polyendocrine syndrome type I and, 303

Altered peptide ligands (APLs), in immunomodulatory vaccination, 445, 448–449

Aluminum salts, chronic renal failure and, 110, 112–114

Amenorrhea, chronic renal failure and, 116
depression and, 67–68

Amine precursor uptake and decarboxylation (APUD), ectopic proopiomelanocortin syndrome and, 197

L-Amino acid decarboxylase (AADC), aromatic, in autoimmune polyendocrine syndrome type II, 382

Amino acids, animal sources of. See *Animal proteins.*
in oxalate metabolism, 930–931
renal transport of dibasic, 952–953
defects of. See *Cystinuria.*

Ammonium acid urate stones, gastrointestinal disease associated with, 981, 994–995

Ammonium excretion, evolution of, 896–897
in idiopathic uric acid nephrolithiasis, 905–908
bowel disease and, 981, 994–995
treatment of, 909
normal physiology of, 900–901

Amputation, lower extremity, diabetes mellitus and, 603–606, 609
prevention of. See *Diabetic foot ulceration.*

Amygdala, major depression and, 51–52
obesity and, 181
stress response and, 44
neuroimaging of, 51–52

Analgesia, stress-induced, 8

Anaphylaxis, epinephrine response to, 84, 88, 91

Androgen(s), for rheumatoid arthritis, 6–7

Anemia(s), autoimmune polyglandular syndrome type I and, 300, 309
autoimmune polyglandular syndrome type II and, 342, 380–381
diagnostic approach to, 342–344, 346
treatment of, 349–350
autoimmune polyglandular syndrome type IV and, 436
type 1A diabetes mellitus-associated autoimmunity and, 402–403

Anergy, in autoimmunity, 276, 420–425
monoclonal antibodies and, 461–463
therapeutic, 278–279

Animal models, of autoimmune polyglandular syndromes, **431–439**
type I, 431–432
type II, 432–434
type III, 434–435
type IV, 435–437
of autoimmunity, 275–278
of immunomodulatory vaccination, 442–445
of immunosuppressive therapy, for type 1 diabetes mellitus, 478–479
of monoclonal antibodies, in self-tolerance restoration, 464–468
of rheumatic diseases, 3–5, 8
of T-lymphocyte development, 274

Animal proteins, nephrolithiasis and, as risk factor, 1036, 1053–1054
background on, 1023–1024
hyperoxaluria and, 942–943
intake, salt, and recurrences, 1024
recommendations on, 943, 1025–1026
uric acid, 902–903
urine supersaturation impact of, 859

Ankle-brachial index, in diabetic foot assessment, 635–636

Anorexia nervosa, depression and, 67–68
growth hormone effects of, 178–179
hypothalamic-pituitary-adrenal axis effects of, 183–184
thyroid function effects of, 176–177
hypothyroidism versus, 177

Antalarmin, stress response and, 42–44

Antibiotics, systemic, for noninfected diabetic foot ulcers, 609

Antibodies, antigen recognition by, 262–265
B-cell source of, 263
in autoimmunity. See *Autoantibodies*.
insulin (human versus animal), for diabetes mellitus, 729, 733, 738–744

Anticandidal drugs, autoimmune polyglandular syndrome type I indications for, 310–311

Anti-CD3 antibody therapy, immunomodulatory vaccination and, 451

Antidepressants, for major depression, ovarian steroids' influence on, 72–73
for sleep disorders, 22

Antigen(s), in autoimmunity therapy, 278–279
in immunology, processing and presentation of, 267–270
class I pathway, 267–269
class II pathway, 269–270
co-stimulation signals, 461
recognition of, B-lymphocytes and, 262–264
monoclonal antibodies and, 458–460
T-lymphocytes and, 264–265
modulation of, in self-tolerance restoration, 463–464

Antigen-expressing cells (APC), autoimmunity and, **411–430**
conclusions about, 426
differential expression of, 413, 416–420
introduction to, 411–412
lymphocyte activation and, 266–267, 412–413, 461
peripheral, 412–413, 420–425
self-molecule expressing types of, 420–425
thymus and, 276–277, 412–413
in immunomodulatory vaccination, 446, 448, 450
in type 1 diabetes mellitus immunosuppressive therapy, 478–480

Antigenic peptide, in autoimmunity, 411

Antigliadin antibodies, in celiac disease, 392–393

Antihypertensive agents, in primary aldosteronism screening, 620–621, 624–626, 629

Anti-idiotypic antibodies, in self-tolerance restoration, 468

Antithyroid drugs, for autoimmune polyglandular syndrome type II, 349

Apo C-III gene, polymorphisms of, in type-2 diabetes mellitus, 559–560

Apoptosis, in autoimmunity, 274–275, 423

Applicability, of evidence-based diagnosis, 576–580

Approximation programs, computer iterative, for nephrolithiasis analysis, 857, 1038–1040

Arginine, in cystinuria pathology, 951–953
  molecular basis of, 953–960

Arginine vasopressin (AVP), diabetes insipidus and, 128–129
  neuroendocrine-immune regulatory loop and, 1–2
    animal models of, 5
  syndrome of inappropriate antidiuretic hormone and, 123
  water homeostasis and, excess secretion effects of, 123–128
    insufficient secretion effects of, 128–135
    normal physiology of, 121–123

Arginine vasopressin V_2 receptors, water homeostasis and, 122–123, 133–135

Arousal. See also *Sleep and sleep cycle*.
  major depression and, 38–40, 54–55
  obesity and, 180–181

Arrhythmias, cardiac, epinephrine toxicity and, 88–90
    hypercalcemia and, 156

Ascites, with cirrhosis, hypoosmolar hyponatremia associated with, 124, 128

Ascorbic acid, in oxalate metabolism, 930–931, 942–943

Aspirin therapy, for diabetic retinopathy, **779–792**
    adverse effects of, 781
    as antiplatelet agent, 780
    clinical problem of, 779–780
    research evidence review, 780–781
    systematic review of, 781–792
      discussion on, 789
      methods for, 781–782
      results of, 783–789

Assays, for autoimmune polyendocrine syndrome type II, 370–373, 381
  for autoimmunity, 412–413
  of peripheral antigen-expressing cells, 421–422, 425

Asthma, bronchial, glucocorticoid therapy withdrawal analysis, 754, 758, 761–762, 764–765, 768–769, 772
  evidence-based medicine example, 524

Atrial natriuretic peptide (ANP), in syndrome of inappropriate antidiuretic hormone secretion, 125

Atypical depression, as clinical syndrome, 38–40
  long-term medical consequences of, 37, 53–55
  stress response and, 37, 40–46

Autoantibodies, in autoimmune diseases, 274–275
  in autoimmune polyendocrine syndrome type II, **369–389**
    adrenal cortex, 370–376
    clinical applications of, 382–385
    diagnostic approach to, 342–347
    organ-specific, 344, 346, 379–382
    other adrenal, 378–379
    steroid-producing, 376–378

Autoimmune disease(s). See also *specific disease, e.g., Systemic lupus erythematosus (SLE)*.
  AIRE regulator of, population genetics and functions of, **321–338**, 392
  animal models of, 8 3–5
  autoantibodies in, 274–275
  genetic link between, 278
  immunomodulatory vaccination in, **441–456**
    anti-CD3 antibody treatment and, 451
    autoimmune polyendocrine syndromes, 442
    controversial effects of, 448–449
    cytokines role, 443–445, 449–450
    dendritic cell vectors and, 450–451
    DNA vaccines, 445–449
    immunologic vaccines, 442–443
    NOD mouse, 442

Autoimmune disease(s) (*continued*)
peptide/protein vaccines, 443–445, 448–449
trends and conclusions, 441, 452
prevalence of, 457

Autoimmune lymphoproliferative syndrome (ALPS), in neonates, 290–291

Autoimmune polyendocrine syndromes. See *Autoimmune polyglandular syndromes (APS)*.

Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). See also *Autoimmune polyglandular syndrome type I (APS I)*.
characteristics of, 295, 321, 431

Autoimmune polyglandular syndrome type I (APS I), **295–320**
Addison's disease and, 314
AIRE gene responsible for, 295, 322
animal models of, 431–432
future applications of, 335–336
mutations of, 326–329, 333–335
animal models of, 431–432
characteristics of, 295, 321–322, 340
clinical manifestations of, 295–303
morphology aspects, 305
variation of, 303–304
diagnostic approach to, 305–310
follow-up recommendations for, 309–310
immune defect in, 296–297
prevalence of, 295–296
prognosis of, 316–317
treatment of, 310–316

Autoimmune polyglandular syndrome type II (APS II), **339–352**
Addison's disease and. See *Addison's disease*.
animal models of, 432–434
assays for, 370–373, 381
autoantibodies in, **369–389**
adrenal cortex, 370–376
clinical applications of, 382–385
functional assessment of, 342–347
organ-specific, 344, 346, 379–382
other adrenal, 378–379
steroid-producing, 376–378
characteristics of, 322, 356–357, 369–370
clinical aspects of, 340–342, 356–357
cytotoxic T-lymphocyte antigens and, 362–364
definition of syndrome, 356–357
diagnostic approach to, 342–347
genetics of, **353–368**, 369, 372
CTLA-4 polymorphism and, 362–364
HLA haplotypes in, 354–356, 358–361, 363–364
introduction to, 353–354
MICA-A polymorphism and, 361–362
principles of, 354–356
human leukocyte antigen haplotypes in, MICA-A polymorphism of, 361–362
scope of, 354–356, 358–361
screening tests for, 346, 374–375, 379, 384
treatment of, 347–350

Autoimmune polyglandular syndrome type III, animal models of, 434–435

Autoimmune polyglandular syndrome type IV, animal models of, 435–437

Autoimmune polyglandular syndromes (APS), animal models of, **431–439**
characteristics of, 321–322, 339–340
immunomodulatory vaccination and, 442
in neonates, 286–291
type I. See *Autoimmune polyglandular syndrome type I (APS I)*.
type II. See *Autoimmune polyglandular syndrome type I (APS I)*.
type III, 434–435
type IV, 435–437

Autoimmune thyroid disease (AITD),
autoimmune polyendocrine syndrome type I and, 299–300
diagnostic approach to, 306, 308
autoimmune polyendocrine syndrome type II and, 370–371, 373, 375, 378
animal models of, 433–434
autoantibody specifics of, 369, 379–380
clinical applications of, 382–384
diagnostic approach to, 342–347
treatment of, 348–350
without Addison's disease, 341–342
autoimmune polyendocrine syndrome type III and, animal models of, 434–435
autoimmune polyendocrine syndrome type IV and, animal models of, 436
genetics of, 396–397
goitrous versus atrophic, 397
type 1A diabetes mellitus-associated autoimmunity and, 396–397

Autoimmunity, **411–430**
animal models of, 275–278
definition of, 274
Fas ligand system and, 274–275, 290–291
genetics of, 275–276, 278, 412–420
neonatal syndromes in, 287, 289–291
principles of, 354–356
HLA system and, 275–276
in neonates, 286–291
introduction to, 274, 411–412
monoclonal antibodies for, **457–475**
CD3 antibodies and, 458–460, 466–469
diabetes relevance, 465–466
diabetes reversal with, 466–467
introduction to, 457–458, 469–470
mode of action, 461–464
receptor specificities, 458–461
tolerogenic properties of, 464–465
regulatory T-cells and, 277–278
self-molecule expression with, cells involved in, 420–425
conclusions about, 426
differential, 413, 416–420
in thymus and lymphoid organs, 412–415
therapy for, 278–279
thymus expression and, 276–277
tolerance and, 274–279, 412, 417. See also *Self-tolerance*.

Awareness, by physicians, as evidence-based medicine factor, 805–806

Azathioprine, for autoimmune polyglandular syndrome type I, 311–312

B

Bacillus Calmette-Guerin, in type-1 diabetes mellitus intervention trial, 484

Bacteria, intestinal, oxalate metabolism by, 929–930, 939
nephrolithiasis from, 1008, 1041

Bangladeshi, qualitative research on diabetes health beliefs, 587–596
background on, 587–588
methods for, 588–594
results analysis, 594–596

B-cell receptor (BCR), antigen recognition by, 263–264, 267

B-cells. See *B-lymphocytes*.

β-cells. See *Pancreatic β-cells*.

Behavior change, in qualitative research, 595–596

Benefit/risk analysis, in evidence-based medicine, 824

Bias, in diabetes mellitus practice guidelines, 818, 823–824
in evidence-based diagnosis, 622–623, 627–628
in evidence-based medicine, 523, 569, 587, 819, 821, 823–824
in osteoporosis trials, 661–662
in qualitative research, 584

Bicarbonate salts, for hypocitraturia, 1058–1059

Bile acid malabsorption, with small bowel resection, diet recommendations for, 990–993
oxalate metabolism and, 986–988

BioBreeding rat model, in immunosuppressive therapy, for type I diabetes mellitus, 478
of autoimmune polyglandular syndrome type II, 434–435

Biological symptoms, of major depression, 37–40

Biosynthetic dermis, for noninfected diabetic foot ulcers, 607–609

Biphosphonates, for hypercalcemia, 154–155
for hypercalciuria, 1056

Birth control, chronic renal failure and, 117

Blinding, in osteoporosis trials, 661–662

Blood flow rate, with aspirin for diabetic retinopathy, 789

Blood glucose, fasting, with human versus animal insulin, for diabetes mellitus, 725, 729, 733, 738–744
monitoring of, in type 1 diabetes mellitus immunosuppressive therapy, 482, 490

Blood tests, for nephrolithiasis, 1036–1037
in children, 1010

B-lymphocytes, acquired antigen recognition and, 262–264
HLA system and development of, 273–274
in self-tolerance restoration, 457, 464

B-lymphocytes (*continued*)
in type 1 diabetes mellitus
immunosuppressive therapy, 478, 487

Body language, in qualitative research, 594–595

Body mass index (BMI), sleep apnea and, 29–30

Body weight, depression and amenorrhea similarities of, 68

Bone biopsy(ies), chronic renal failure indications for, 112–114

Bone disease, adynamic (aplastic), 110

Bone marrow transplantation, glucocorticoid therapy withdrawal analysis, 760, 765, 767

Bone mineral density (BMD).
See also *Bone resorption*.
and fractures relationship to postmenopausal osteoporosis therapies, metaanlyses summary of, **659–679**
absolute differences in event rates, 666–667
background on, 659–660
bone density changes and fractures results, 669–674
bone density results, 667–669
comparison of treatment effects between, 663
management implications, 674–676
methodologic quality of studies, 660–663
nonvertebral fractures results, 665–666
vertebral fractures results, 663–665
evidence-based medicine example, 523–524
melancholic depression and, 39, 53

Bone resorption. See also *Bone mineral density*.
of osteoclast, in hypercalcemia, 143–147, 151
inhibition of, 152–154
with chronic renal failure, 109–112
management of, 111–114

Bone turnover. See *Bone resorption*.

Bowel disease, nephrolithiasis from, **979–999**
ammonium acid urate stones, 994–995
epidemiology of, 979–980
small bowel resection and, 985–994
total colectomy with ileostomy and, 980–984

Brain injury, glucocorticoid therapy withdrawal analysis, 764

Bronchial carcinoids, ectopic proopiomelanocortin syndrome and, 198, 204–205

Bronchogenic carcinoma, syndrome of inappropriate antidiuretic hormone secretion associated with, 123–125

C

Calciferol sterols, for autoimmune hypoparathyroidism, 312–314

Calcification, with chronic renal failure, extraskeletal, 110–111
skeletal, 109–110

Calcitonin (Miacalcin), for hypercalcemia, 152–153
in postmenopausal osteoporosis trials, 661–676

Calcitriol, chronic renal failure and, 108–110, 112–113
for autoimmune hypoparathyroidism, 314
in calcium homeostasis, 871–872

Calcium, in postmenopausal osteoporosis trials, 661
pathogenetic role in nephrolithiasis, animal protein and sodium in, 875–876, 942–943
citrate in, 876–877
dietary intake versus supplements, 871–875
hyperoxaluria and, 940–943
in children, 1012–1013
recommendations on, 877–878, 943
hypercalciuric, 869–871
hyperuricosuric, 915–923
in children, 1010–1012
small bowel resection and, 985–994
solubility and, 856–857
uric acid, 905–908
serum analysis of, for nephrolithiasis, 1010, 1036

Calcium homeostasis, chronic renal failure and, diagnosis of, 111–114

extra skeletal effects of, 110–111
management of, 111–114
pathophysiology of, 108–109
skeletal effects of, 109–110
extracellular deficiency of. See *Hypocalcemia*.
extracellular elevation of. See *Hypercalcemia*.
nephrogenic diabetes insipidus and, 129, 133–134
normal physiology of, 871–872

Calcium load test, for nephrolithiasis, 1041–1042

Calcium oxalate (CaOx) stones, from bowel disease, 981
small bowel resection and, 985–994
total colectomy with ileostomy and, 983–984
hyperuricosuria and, 920–921
ion-activity products of, 1031–1033, 1038–1040
nutritional aspects of, 1019–1023
background on, 1019–1020
hyperoxaluria and, 940–943
low versus high calcium intake, 1020–1023
recommendations on, 943, 1025–1026
renal. See *Nephrolithiasis*.
solubility and, 856–857
uric acid effect on, 919–920
with urine supersaturations, 859–860, 1020–1023
small bowel resection and, 989–990

Calcium phoshpate stones, ion-activity products of, 1031–1033, 1038–1040

Calcium salts, for autoimmune hypoparathyroidism, 312–314
for chronic renal failure, 110, 112

Calcium sensing receptor, in hypercalcemia, 144–145

Calcium supplement, with small bowel resection, 992–993

Calcium-mimetic drugs, for hypercalcemia, 154

Calciuresis, for hypercalcemia, 152–153

Calculi, pathophysiology of. See *specific substrate*.
renal. See *Nephrolithiasis*.
ureter. See *Ureteral calculi*.
urinary. See *Urolithiasis*.

Cancer, of thyroid. See *Thyroid cancer*.

Cancer screening, predictive value of, 574

Candidiasis, mucocutaneous (MC), autoimmune polyglandular syndrome type I and, characteristics of, 295–297, 304, 321
diagnostic approach to, 306, 309
treatment of, 310–311

Captopril, for cystinuria, 967

Carcinoid tumors, ectopic proopiomelanocortin syndrome and, 198, 204–205
imaging studies of, 214–216

Carcinoma. See *specific type, e.g., Small cell lung carcinoma (SCLC)*.

Cardiac arrest, epinephrine actions in, 85
epinephrine toxicity in, 89–97
psychological stress and, 89–90
significance of, 90–97

Cardiac arrhythmias, epinephrine toxicity and, 88–90
hypercalcemia and, 156

Cardiac disease. See *Heart disease*.

Cardiovascular event risks, in diabetes with albuminuria complications, **537–551**
categorical variables of, 540–541
characteristics of, 540–541
continuous variables of, 540–541
date collection over time versus at point in time, 542–543
epidemiologic establishment of, 539
etiology and pathogenesis implications of, 546–547
HOPE study baseline measurements and factors, 541
HOPE study data analysis, 543–1267
HOPE study design, 538–539
HOPE study population, 539–540
measurements, exposures, and factors of, 540–541
outcome constructions, 541–542
population characterization, 539
progressive variables of, 541
scope of, 537–538, 548–550
statistical expression of, 545–546
therapy implications of, 548–549

Cardiovascular toxicity, of epinephrine, with acute severe stress, 86–87
with cardiac arrest, 89–97

Cardiovascular toxicity (*continued*)
with preexistent heart disease, 88–89

Case notes, for qualitative research, 585, 590

Case-control studies, of gene-environment interactions in type-2 diabetes mellitus, 557, 562

Case-only studies, of gene-environment interactions in type-2 diabetes mellitus, 558

Catecholamines, major depression and, 47–48
stress response and, 83–84, 96
24-hour levels of, in sleep disorders, 21–22, 28

CD3 antibodies, immunomodulatory vaccination and, 451
in self-tolerance restoration, antigenic modulation and, 463–464
clinical applicability of, 467–469
diabetes reversal and, 466–467
immune mediation of, 469
lymphocyte receptors and, 458–460
target cell depletion by, 462–463

CD4 antibodies, in self-tolerance restoration, cell coating and, 463
lymphocyte receptors and, 458–460
target cell depletion by, 462–463
tolerogenic properties of, 464–465

CD4+ T-cells, in immunology, as helper subsets, 265, 273, 277
neonatal, 285–286
in immunomodulatory vaccination, 443–444, 447–450

CD8+ T-cells, immunologic role of, 265, 267, 269, 273
in autoimmunity, 277

CD40/CD40 Ligand, in co-stimulation response, 265

Celiac disease, autoimmune polyendocrine syndrome type I and, 302
autoimmune polyendocrine syndrome type II and, 371, 381
diagnostic approach to, 343–345, 347
genetics of, 362–364
treatment of, 350
type 1A diabetes mellitus-associated autoimmunity and, 392–396

Cell coating, in self-tolerance restoration, 463

Central diabetes insipidus (CDI), pathophysiology of, 129–130
systemic disorders associated with, 129–133

Central nervous system disorders, syndrome of inappropriate antidiuretic hormone secretion associated with, 124, 126–127

C-fos oncogene, in osteoclast bone resorption, 145

Chelation therapy, for cystinuria, 966–967

Chemolysis, for struvite calculi, 971

Chicken models, of autoimmune polyglandular syndrome type II, 433

Childhood nephrolithiasis, **1001–1015**
clinical manifestations of, 1001–1002
cystinuria, 1007
Dent's disease, 1004–1006
diagnosis of, 1010
genetics of, 1003–1007
hematuria with, 1002–1003, 1006
hypercalciuria, 1002–1003, 1010–1012
infection-related, 1008–1009
miscellaneous causes, 1009
prevalence of, 1001
preventive medical therapy for, 1012–1013
primary hyperoxaluria, 1006–1007
Seyberth syndrome, 1003–1004
uric acid calculi, 1007–1008

Childhood trauma, major depression from, 37–38

Chinese databases, in iodized salt for iodine deficiency review, 684, 686

Chloroquine, for hypercalcemia, 155

Cholecystokinin, autoimmune polyendocrine syndrome type I and, 300–301

Cholestyramine, for autoimmune polyglandular syndrome type I, 302
for enteric hyperoxaluria, 940
for hyperoxaluria, 1056

Chromosomes. See *Genetics*.

Chronic fatigue syndrome, 55

Chronic inflammatory demyelinating polyradiculoneuropathy, glucocorticoid therapy withdrawal analysis, 764

Chronic medical disorders, glucocorticoid withdrawal schemes for, **751–777**
clinical problem of, 751–753
systematic review of controlled trials on, 753–772
discussion on, 772
methods for, 753–756
results of, 757–772

Chronic obstructive pulmonary disease (COPD), evidence-based medicine example, 524
glucocorticoid therapy withdrawal analysis, 763, 765–766, 769–770, 772
syndrome of inappropriate antidiuretic hormone secretion associated with, 124, 127

Chronic renal failure, endocrine abnormalities in, **107–119**
diagnosis of sequelae, 111–114
erythropoietin deficiency as, 114–116
extraskeletal effects of, 110–111
management of sequelae, 111–114
pathophysiology of, 107–109
sexual dysfunction with, 116–117
skeletal effects of, 109–110
epidemiology of, 107

Cinahl, as evidence-based medicine resource, 636

Circadian rhythm/pacemaker. See also *Sleep and sleep cycle*.
anorexia nervosa and, 184
cytokines impact on, 26–28
growth hormone and, 177
sleep and, 15–16, 20

Cirrhosis, with ascites, hypoosmolar hyponatremia associated with, 124, 128

Citrate, hypocitraturia and, as treatment, 1058–1059
background on, 1024–1025
dietary risk factors of, 1025
nephrolithiasis with, 885–891
primary hyperoxaluric and, 937
renal handling of, 885–888
acid-base parameters effect on, 888
pathogenic, 889–891
age and sex differences in, 888–889
in proximal tubule, 887–888
kidney reabsorption, 886
molecular mechanisms of transport, 887
other regulators of, 888
overall, 885–886
tubule transport, 886–887
uric acid nephrolithiasis and, 905–908
in children, 1011

Citrate supplements. See also *Magnesium citrate; Potassium citrate*.
for bowel disease, 984–985, 992

Class I pathway, of antigen processing/presentation, 267–269

Class II pathway, of antigen processing/presentation, 269–270

Claudin-16 protein, hypercalciuric nephrolithiasis association with, 880

Clinical expertise, in evidence-based medicine, 587, 793–799, 801, 803

Clinical outcomes, of diabetes mellitus complications, 541–542
of evidence-based thyroid medicine, 810

Clinical practice guidelines, adherence to development standards, **817–825**
bias in, 818, 823–824
data analysis, 819
discussion on, 823–825
guideline assessment, 819–820
guideline selection, 818
inclusion criteria, 818
methods for evaluating, 818–819
mythological standards satisfied by guidelines, 820–822
predictors of, 822
physicians' role in, 805–807
results of analysis, 819–823
source of published, 817
study limitations, 824–825
evidence-based. See also *Evidence-based medicine*.
applications of, 576–580, 587, 793–794
limitations of, 807–810
collecting information for, 794–795, 801–802
deficiencies of, 807–808
definition of, 793–794
flexibility and innovation of, 809
for thyroid disease, **793–815**
clinical algorithm for, 794, 800
clinical pathways for, 794, 800
computers for implementation, 807
development of, 802–805
implementation of, 805–807

Clinical practice guidelines (*continued*)
individual impact of, 810–811
limitations of, 807–810
review of available, 794, 796–799
societal impact of, 810–811
tools for advocating, 795, 800
impact of, 810–811
incorporating cost-effective analysis into, 805
maintenance of, 808–809
steps in development of, 802–805

Clinical trials. See also *Intervention trials.*
benefit versus risk trade-off in, 823–825
Cochrane Metabolism and Endocrine Disorders Review Group evaluation of, **613–617**
in evidence-based medicine, 522–525, 614–615
initiation and design of, 616–617
on glucocorticoid withdrawal schemes, 753–754, 776–777
on iodized salt for iodine deficiency, 683–684, 697
on thyroxine suppression therapy, 701–703, 719–720
qualitative versus quantitative, 585–586, 599

Clinician surveys, as evidence-based practice resource, 794–795, 801

CLIP fragment, in immunology, 269–270

Clonal indifference, in immunology, 276

Coagulum pyelolithotomy, for urolithiasis, 1072–1073

Cochrane Collaboration, 614, 620
Wounds Group of, 635–636

Cochrane Controlled Trials Register, 614, 684, 702, 759
Wounds Group Specialized, 636

Cochrane Database of Systematic Reviews, as evidence-based medicine resource, 529–530, 614–616
of glucocorticoid withdrawal schemes, 754, 757, 759
conclusions from, 759, 764–765
of iodized salt for iodine deficiency, 683–684
of primary aldosteronism screening, 620
of thyroid nodule pharmacotherapy, 702, 714–716

Cochrane Diabetes Group, 614–615

Cochrane Library, 530, 614–617, 726, 783
diabetic foot ulcer studies, 605, 607, 635

Cochrane Metabolism and Endocrine Disorders Review Group (CMED), **613–617**
editorial base of, 615, 617
historical evolution of, 613–615
major output of, 614
primary concern of, 615
systematic review process of, 616–617
web site for, 616

Cognition, obesity effects on, 180

Cohort studies, of gene-environment interactions in type-2 diabetes mellitus, 557–558

Colitis. See *Ulcerative colitis.*

Colony-stimulating factors (CSF), hypercalcemia and, 145–147

Committees, guideline, in evidence-based medicine, 823–824

Common variable immunodeficiency, type 1A diabetes mellitus-associated autoimmunity and, 399–400

Complement system, in neonates, 283–285

Computed tomography (CT) scan, for cystinuria analysis, 963
for ectopic Cushing's syndrome, 214–216
for nephrolithiasis analysis, 1033–1034

Computer iterative approximation programs, for nephrolithiasis analysis, 857, 1038–1040

Computers, for evidence-based medicine implementation, 807

Concealment, of randomization, in osteoporosis trials, 660, 662–663

Confounding, in qualitative research, 584

Congenital rubella syndrome, type 1A diabetes mellitus-associated autoimmunity and, 401–402

Congestive heart failure, hypoosmolar hyponatremia associated with, 124, 128

Contemporaneous material analysis, for qualitative research, 585, 590

Conventional narrative literature reviews, as evidence-based practice resource, 795–799, 801

Core stress system, components of, 41
in major depression, 47–51

Coronary artery disease (CAD). See *Heart disease*.

Corpus luteum, hormonal regulation of, 65
in major depression, 68–70

Corticosteroids. See also *specific type, e.g., Mineralocorticoids*.
for neurosarcoidosis, 131–132
for rheumatoid arthritis, 5–6
immune/inflammatory process inhibition by, 2–3

Corticotrope cells, of pituitary, in POMC modification and processing, 194–195
in POMC transcription regulation, 192, 194
obesity effects on, 179

Corticotropin. See *Adrenocorticotropic hormone (ACTH)*.

Corticotropin-dependent hypercortisolism, 196–197
diagnosis of, 207–209
differential diagnosis of, 209

Corticotropin-releasing hormone (CRH), ectopic tumors producing, classification of, 197–199
effects on proopiomelanocortin, 192–195
fibromyalgia and, 8–9
major depression and, 48–51
amenorrhea similarities with, 67–68
atypical, 53–55
neuroendocrine-immune regulatory loop and, 1–3
animal models of, 4–5
obesity effects on, 179–180
POMC gene transcription and, 192, 194
rheumatoid arthritis and, 5–7
sleep effects of, 17–19, 25
stress response and, 65–67
as core component, 41–44
systemic lupus erythematosus and, 7

Corticotropin-releasing hormone stimulation test, for ectopic Cushing's syndrome, 210, 212–213
for fibromyalgia, 8–9
in obesity, 182

Cortisol production/secretion, cytokines impact on, 26–31
diurnal patterns of, 8–9, 207
ectopic Cushing's syndrome and, 205–206
fibromyalgia and, 8–9
in glucocorticoid withdrawal schemes, 752
insomnia and, 21–24
major depression and, atypical correlations, 54–55
melancholic correlations, 48–51
pathophysiology of, 46–48, 70
neuroendocrine-immune regulatory loop in, 1–3
animal models of, 3–5
nonthyroidal illness syndrome and, with fasting, 162
obesity effects on, 179–181, 185
Cushing's syndrome and, 181–182
pseudo-Cushing's syndrome and, 182–183
rheumatoid arthritis and, 5–6
sleep and, age impact on, 20, 28
deprivation impact on, 20–21
disordered/disturbed physiology of, 21–26
normal physiology of, 3–7
stress response and, 44, 67–68
neuroimaging of, 52

Cost-effective analysis, in evidence-based practice development, 801–802, 805

Co-stimulation signals, in self-tolerance restoration, 461

Cost-utility/benefit issues, as evidence-based medicine factor, 615, 810–811

C-peptide, in type 1 diabetes mellitus immunosuppressive therapy, 478, 482, 484, 486, 490

CpG islands, in POMC gene transcription, 193

Creatinine analysis, for nephrolithiasis, serum, 1010, 1036
urine, 1038

Crohn's disease, glucocorticoid therapy withdrawal analysis, 759–760, 764, 766–767
nephrolithiasis from, 979, 982
surgery associated with. See *Small bowel resection; Total colectomy*.

Cross-sectional case studies, of gene-environment interactions in type-2 diabetes mellitus, 557–558

Crystallization, as basis of nephrolithiasis, 855
  crystalluria versus, 862–864
  inside the nephron, 860–861
  supersaturation resulting in, 858–860

Crystallization inhibitors, bowel disease effects and, 984
  in crystalluria versus stone formation, 862–864
  in hyperuricosuric calcium nephrolithiasis, 919
  inside the nephron, 860–861

Crystallography, for nephrolithiasis analysis, 909, 918–919, 1033–1034

Crystalluria, versus stone formation, 862–864

C-src oncogene, in osteoclast bone resorption, 145

Cushing's syndrome, clinical features of, 200, 202
  corticotropin-dependent, 196–197, 207–209
  ectopic, syndrome of. See *Ectopic proopiomelanocortin syndrome*.
    tumor classification in, 191, 197–199, 203–205
  endocrine workup for, 205–214
    hypercortisolism differential diagnosis in, 209–214
    hypercortisolism establishment in, 205–209
  endogenous, 191, 197
  etiologies of, 191, 195
  imaging studies for, 214–216
  obesity and, 180–181
    distinction of pseudo-Cushing's syndrome, 181–182
  sleep disorders in, 25–26

Cyclosporine(s), for autoimmune polyglandular syndrome type I, 311–312
  for type 1 diabetes mellitus, 451, 481

Cystine, concentration of, with nephrolithiasis, 1031–1032
    analysis of, 1040–1041
  renal transport of, 952–953
  urinary excretion rate of, 960–961

Cystine stones, in nephrolithiasis, composition analysis of, 1034, 1040–1041
    in children, 1007
    nutritional aspects of, 1027
    treatment impact on solubility, 857

Cystinuria, **951–977**
  amino acid transport in, 952–953
  classification of, 954–955
  clinical presentation of, 960
  diagnosis of, 960–964
  dietetic factors of, 1052–1054
  drug therapy for, 1059
  epidemiology of, 952
  future directions for, 969
  history of, 951–952
  in childhood nephrolithiasis, 1007
  intestinal cystine transporters and, 953
  molecular basis of, 953–960
    non-Type I, 958–960
    rBAT glycoprotein and, 952, 954–956
    recent advances in, 954–956
    traditional classification based on, 954
    Type I, 956–958
  non-Type I pathology, 958–960
  other noncalcareous calculi versus, 969–972
  treatment of, 965–969
    medical approach to, 965–967
    surgical approach to, 967–969
  Type I pathology, 956–958

Cytokine receptors, in self-tolerance restoration, 461

Cytokines, atypical depression and, 55
  chronic renal failure and, as bone resorption marker, 112
  for immunomodulatory vaccination, 443–445, 449–450
  hypercalcemia and, 143–149, 151
  in autoimmunity, 265, 277
  in type-1 diabetes mellitus therapy, **477–495**
    early prevention attempts, 481–482
    glucose control trials, 482
    indications for use, 477–479
    introduction to, 477, 491
    prevention trials design issues, 488–490
    prevention trials enrollment, 479–481
    recent intervention trials, 482–488
    trial results, 484–485
  neuroendocrine-immune regulatory loop and, 1–3
  nonthyroidal illness syndrome and, 165
  sleep and, 26–31
    age impact on, 28

disordered/disturbed physiology of, 28–31
normal physiology of, 27–28

Cytosine/guanine content, in POMC gene transcription, 193

Cytotoxic cells, in neonates, 283, 285

Cytotoxic T-lymphocyte (CTL), in immunomodulatory vaccination, 445, 447–448, 451–452

Cytotoxic T-lymphocyte antigen-4 (CTLA-4), activation regulation and, 267, 274
autoimmune disease link to, 278
autoimmune polyglandular syndrome type II and, 362–364

D

Daclizumab (DZB), in type-1 diabetes mellitus intervention trial, 487–488

Database(s), as evidence-based endocrinology resource, 528–529

Daytime sleepiness, excessive (EDS), adrenal insufficiency and, 26
as disordered physiology, 17, 22, 25
cytokines and, 28–31
with Cushing's syndrome, 25

Decision support systems, for evidence-based medicine, 528–529, 613–614, 807

Deep sleep. See *Slow-wave sleep (SWS)*.

Deiodinases, iodothyronine, nonthyroidal illness syndrome and, 160, 164
overexpression of type 3, 165

Dendritic cells (DCs), bone marrow-derived, autoimmune response to, 420–421, 423–425
immunomodulatory vaccination and, 450–451
in immunology, 261, 457
in type 1 diabetes mellitus immunosuppressive therapy, 478, 480

Dent's disease, nephrolithiasis associated with, 877, 879–880
in childhood, 1004–1006
supersaturation variations in, 861

Depression, major, biological symptoms of, 37–40
classification of, 38–40
DSM-IV criteria for, 38
endocrine disorders and, **37–62**
definitions in, 37–40
long-term medical consequences of, 37, 52–55
pathophysiology of, 47–52
stress response and, 40–46
environmental factors of, 64
epidemiology of, 37–38
fibromyalgia association with, 8–9
hypothalamic-pituitary-adrenal axis and, 64
amenorrhea similarities of, 67–68
obesity and, 180
neurovegetative symptoms of, 38–41
ovarian steroids' effects on, 72–73
prevalence in men versus women, 63–64
psychological symptoms of, 38–40
REM sleep and, 19
reproductive hormones and, 68–70
sleep disorders and, 17, 22, 39–40
stress response and, 40–46, 64
amygdala role in, 44
core stress system in, 41, 47–51
CRH system in, 41–44, 48–51
LC-NE system in, 41, 45, 47–48
neurobiology of, 40–46
neuroimaging studies of, 51–52
pathophysiology of, 47–52
phenomenology of, 40–41
prefrontal cortex role in, 41, 44–46
unipolar versus bipolar, 38

Desmopressin test, for ectopic Cushing's syndrome, 211–213

DEXA studies, of bone histomorphometry, in chronic renal failure, 112

Dexamethasone, for autoimmune polyglandular syndrome type II, 348

Dexamethasone suppression test, in anorexia nervosa, 184
in ectopic Cushing's syndrome, high-dose, 209–210
low-dose, 206–207
in fibromyalgia, 9

Di George syndrome, in neonates, 290

Diabetes insipidus (DI), central, 129–133
nephrogenic, 129, 133–135
pathophysiology of, 128–129

Diabetes insipidus (DI) (*continued*)
systemic disorders associated with, 128–129

Diabetes mellitus, autoimmune, immunomodulatory vaccination for, 442–443
latent, endocrinopathy risks with, 380, 383
neonatal, 287–289
Bangladeshi beliefs about, 587–596
background on, 587–588
research methods for, 588–594
results analysis, 594–596
epidemic proportions of, 537
evidence-based diagnosis of, 567–568, 570, 574
evidence-based medicine for, examples of, 524–525, 533, 723–724
guideline development from, 817–825
foot care in, evidence-based practice, **603–611**. See also *Diabetic foot ulceration*.
abstract of, 603–604
biosynthetic dermis for noninfected foot ulcers, 607–609
off-loading of neuropathic ulcer, 607–608
pathophysiology in, 604
preventing ulceration and amputation, 605–606
risk factors for, 604–605
synopsis of, 603, 609
systemic antibiotic therapy for noninfected ulcers, 609
systemic hyperbaric oxygen for, 609
topical growth factors for noninfected ulcers, 607–609
treatment of neuropathic ulcers, 607
health care costs of, 537–538
human versus animal insulin for, systematic review of, **723–749**
background on, 724–725
crossover studies, 729, 733, 740–743
data analysis, 727–728
data extraction form, 727
discussion on, 744–745
excluded trials, 726, 728
hypoglycemic episode results, 729, 733, 738–744
included trials characteristics, 728–732, 734–737
inclusion criteria, 725
insulin antibodies results, 729, 733, 738–744
insulin dose results, 729, 733, 738–744
metabolic control results, 729, 733, 738–744
methods for, 725–727
outcome measures, 725–726
parallel studies, 729, 733, 738–739
quality assessment of, 726–727
results analysis, 728–729, 738–744
results summary, 723–724
search strategies, 726
trials selection, 726
insulin-dependent. See *Type-1 diabetes mellitus (T1DM)*.
intervention trials on, 596–599
maturity onset, of the young, 554
non-insulin dependent. See *Type-2 diabetes mellitus (T2DM)*.
noninsulin-dependent. See *Type-2 diabetes mellitus (T2DM)*.
platelets and thrombosis in, 780
practice guidelines adherence to standards, **817–825**
bias in, 818, 823–824
data analysis, 819
discussion on, 823–825
guideline assessment, 819–820
guideline selection, 818
inclusion criteria, 818
methods for evaluating, 818–819
metholocigal standards satisfied by guidelines, 820–822
predictors of, 822
results of analysis, 819–823
source of published, 817
study limitations, 824–825
qualitative research on, evaluative, 599–600
explanatory, 596–599
exploratory, 587–596
risk of cardiovascular events with albuminuria complications, **537–551**
categorical variables of, 540–541
characteristics of, 540–541
continuous variables of, 540–541
date collection over time versus at point in time, 542–543
epidemiologic establishment of, 539
etiology and pathogenesis implications of, 546–547

HOPE study baseline measurements and factors, 541
HOPE study data analysis, 543–1267
HOPE study design, 538–539
HOPE study population, 539–540
measurements, exposures, and factors of, 540–541
outcome constructions, 541–542
population characterization, 539
progressive variables of, 541
scope of, 537–538, 548–550
statistical expression of, 545–546
therapy implications of, 548–549
uric acid nephrolithiasis with, 904–908
treatment of, 909

Diabetic foot ulceration, foot care for, evidence-based practice in, **603–611**
abstract of, 603–604
biosynthetic dermis for noninfected foot ulcers, 607–609
off-loading of neuropathic ulcer, 607–608
pathophysiology in, 604
preventing ulceration and amputation, 605–606
risk factors for, 604–605
synopsis of, 603, 609
systemic antibiotic therapy for noninfected ulcers, 609
systemic hyperbaric oxygen for, 609
topical growth factors for noninfected ulcers, 607–609
treatment of neuropathic ulcers, 607
patient education for preventing, systematic review of, **633–658**
as component of general education versus usual care, 647, 651
background on, 633–635
complex intervention for patients and doctors versus usual care, 647, 652
data analysis, 636–639
data extraction form, 636, 639
discussion on, 654–656
included study characteristics, 635–636, 640–645
intensive tailored intervention versus usual care, 647, 653–654
intensive versus brief intervention, 645, 647–650
interventions summarized, 639, 645
methods for, 635–639
quality assessment of, 645–646, 656
results analysis, 639, 645, 647–654
search strategies, 702–703
study limitations, 655–656

Diabetic retinopathy, aspirin in, **779–792**
adverse effects of, 781
as antiplatelet agent, 780
clinical problem of, 779–780
contraindications for, 789
research evidence review, 780–781
systematic review of, 781–792
blood flow rate analysis, 789
data analysis, 782
data extraction form, 782
development results of aspirin alone, 786, 788
development results of aspirin with dipyridamole, 786, 788
discussion on, 789
excluded trials, 783
included trials characteristics, 783–785
inclusion criteria, 781
methods for, 781–782
microaneurysm occurrence, 786, 788–789
quality assessment of, 782
relative risk analysis, 786–787
results of, 783–789
search strategies, 791–3–4
overview of, 779
platelet factors, 780
risk factors for, 779–780

Diagnostic and Statistical Manual of Menta Disorders, Fourth Edition (DSM-IV), major depression criteria of, 38

Diagnostic test, in evidence-based diagnosis, applicability to clinical settings, 576–580
properties of, 570–576
reproducibility of results, 576–580
utility of, 568–570, 579–580

Diarrhea, autoimmune polyendocrine syndrome type I and, 300–302
nephrolithiasis associated with, 979, 982

Diarrhea, autoimmune (*continued*)
diet recommendations for, 990–992
surgery impact on. See *Small bowel resection; Total colectomy.*
uric acid, 902

Diet. See *Nutrition.*

1,25 Dihydroxyvitamin D, in chronic renal failure, 108–109
in hypercalcemia, 144, 149–150

Dipyridamole, with aspirin, for diabetic retinopathy, 786, 788

Disability(ies), major depression and, 37

Disease exacerbation/re activation, glucocorticoid therapy for, 752–754, 757
withdrawal analysis, 759, 764–771. See also *Glucocorticoid withdrawal schemes.*

Diuresis, osmotic threshold for, 122–123

Diuretics, thiazide, for hypercalcemia, 152–153
hypercalcemia and, 144, 151–152

Diurnal patterns, of cortisol production, in fibromyalgia, 8–9
loss with ectopic Cushing's syndrome, 207
of sleep, 15–16

DNA vaccines, autoimmune disease and, 445–449

Dorsolateral prefrontal cortex, stress response and, 44–45, 52

Drug therapy, for hyperuricosuric calcium nephrolithiasis, 921–922
for nephrolithiasis, with cystinuria, 1059
with hypercalciuria, 1054–1056
with hyperoxaluria, 1056–1057
with hyperuricosuria, 1057–1058
with hypocitraturia, 1058–1059
with struvite stones, 1060–1061
nephrolithiasis associated with, 1035–1036
hypocitraturic, 890
uric acid, 903, 909

E

Ectodermal dystrophy(ies), autoimmune polyglandular syndrome type I and, 295, 303, 321

Ectopic proopiomelanocortin syndrome, **191–234**
carcinoid tumors in, 198, 204–205
clinical features of, 200, 202
demographics of, 200–201
diagnostic strategies for, 205–216
endocrine workup as, 205–214
hypercortisolism differential diagnosis as, 209–214
hypercortisolism establishment as, 205–209
imaging studies as, 214–216
epidemiology of, 197–201
etiologies of, 216–217
pancreatic islet cell tumors in, 198, 203–204
POMC gene modification and processing in, corticotrope cells in, 194–195
ectopic tumor production in, 195
POMC gene transcription regulation, corticotrope cells in, 192, 216
ectopic tumor production in, 192–194, 216
prevalence of, 197–199
proopiomelanocortin synthesis and secretion in, 192–197
hypersecretion effects of, 196–197
modification and processing, 194–195
transcription regulation, 192–194
small cell lung cancer in, 198, 203–204
tumor classification in, 197–199, 203–205
validation criteria for, 191–192

Edema-forming states, hypoosmolar hyponatremia with, 124, 128

Editorial team, for clinical trials, 615, 617

Edmonton protocol, for type 1 diabetes mellitus immunosuppressive therapy, 485–487

Effective arterial blood volume (EABV), in hypoosmolar hyponatremia, 128

Efferent pathways, of epinephrine, in acute severe stress, 82–83

Electroencephalography (EEG), of sleep cycles, 16–17, 27

Electrohydraulic lithotripsy (EHL), with percutaneous nephrostolithotomy, 1070
with ureteroscopy, 1071–1072

Electrolyte imbalance(s), autoimmune polyendocrine syndrome type I and, 300–301
diagnostic approach to, 306–310
treatment of, 310, 312–315

Electrolyte intake, as nephrolithiasis risk factor, 1053

EMBASE, as evidence-based medicine resource, 614, 620
in diabetes mellitus foot care, 605, 607, 636

Encephalomyelitis, experimental autoimmune, 412, 417, 419–420

Encephalopathy, autoimmune polyendocrine syndrome type I and, 305

Endocrine disorder(s), chronic renal failure and, **107–119**
diagnosis of sequelae, 111–114
erythropoietin deficiency as, 114–116
extraskeletal effects of, 110–111
management of sequelae, 111–114
pathophysiology of, 107–109
sexual dysfunction with, 116–117
skeletal effects of, 109–110
ectopic proopiomelanocortin syndrome and, 205–214
hypercortisolism differential diagnosis in, 209–214
hypercortisolism establishment in, 205–209
hypercalcemia with, 142
major depression and, **37–62**
definitions and classifications, 37–40
long-term medical consequences of, 37, 52–55
pathophysiology of, 47–52
stress response and, 40–46

Endocrine replacement therapies, for autoimmune polyglandular syndrome type I, 312

Endocrinology, evidence-based. See *Evidence-based diagnosis; Evidence-based medicine.*

Endogenous metabolism, of oxalate, 930–931

Endomysial antibody, in celiac disease, 394

Endoplasmic reticulum (ER), in immunology, 268–269

End-organ function, in autoimmune polyendocrine syndrome type II, 344, 346, 381–383
treatment indications of, 347–350

β-Endorphin, obesity and, 180
stress response and, 65–67, 174–175

Enteric hyperoxaluria (EH), 939–940
small bowel resection association with, 985–986
treatment of, 990–994

Enterochromaffin cells, autoimmune polyendocrine syndrome type I and, 301

Environment, as major depression factor, 64
as type-2 diabetes mellitus etiology, 556
genetic interactions with, 553–556
evidence of, 556–557
proven examples of, 559–562
study design considerations, 557–558, 562

Enzymatic disorders, monogenic, uric acid nephrolithiasis with, 903–904

Enzyme linked immunosorbent assays (ELISA), for autoimmune polyendocrine syndrome type II, 372, 381

Epidemiologic analyses, of risk factors, **537–551**
categorical variables of, 540–541
characteristics of, 540–541
continuous variables of, 540–541
date collection over time versus at point in time, 542–543
etiology and pathogenesis implications of, 546–547
measurements, exposures, and factors of, 540–541
outcome constructions, 541–542
population characterization, 539
progressive variables of, 541
research establishment of, 539
scope of, 537–538, 548–550
statistical expression of, 545–546
therapy implications of, 548–549

Epinephrine, anaphylaxis and, 84, 88, 91
stress response role of, **79–106**
actions of, 84–85
in cardiac arrest, 85
adrenosympathetic system in, 83
afferent pathways of, 81–82
categorizations in, 80–81

Epinephrine, anaphylaxis (*continued*)
efferent pathways of, 82–83
hormone responses in, 80, 83
neuroendocrinology of, 80
plasma concentrations in acute severe stress, 83–84
plasma kinetics of, 85–86
toxicity of, 86
cardiovascular effects of, 86–87
in cardiac arrest, 89–97
metabolic effects of, 87–88
with preexistent heart disease, 88–89

Equilibrium concentration product, in nephrolithiasis physiochemistry, 855–857

Erythema, autoimmune polyendocrine syndrome type I and, 303

Erythrocyte sedimentation rate (ESR), in rheumatoid arthritis, 5–6

Erythropoietin (EPO), recombinant human, for chronic renal failure, 114–116

Estradiol, hypothalamic-pituitary-gonadal axis regulation of, 65
major depression and, 69–70

Estrogen(s), hypothalamic-pituitary-gonadal axis regulation of, 65
leuprolide administration and, 72

Estrogen replacement therapy (ERT), for autoimmune polyglandular syndrome type II, 349
for hypercalcemia, 155
for premenstrual syndrome, 72
in chronic renal failure, 116–117
major depression effects of, 72–73
sleep effects of, 20

Ethacrynic acid (Edecrin), for hypercalcemia, 152–153

Etidronate, in postmenopausal osteoporosis trials, 661

Evidence, definition of, 522–523
hierarchy of, benefit versus risk trade-off in, 823–825
in evidence-based medicine, 522–525, 824
in qualitative research, 585

Evidence assessment, in evidence-based practice development, 803–804

Evidence-based diagnosis, **567–581**
applicability to clinical settings, 576–580
clinical scenarios of, 567–570, 574, 578, 580
systematic reviews of, for primary aldosteronism screening, **619–632**
test properties in, 570–576
likelihood ratios/probabilities, 574–577, 579
calculation of, 580–581
predictive value, 573–574
receiver operating characteristic curve, 571–573
sensitivity, 570–571
specificity, 570–571
utility of, 568–570, 579–580

Evidence-based medicine, **521–526**
as problem-solving strategy, 521–522
as value-laden process, 587
clinical expertise context of, 587, 793–799, 801, 803, 809
collecting information for, 794–795, 801–802
for endocrinology practice, **527–535**
evolution of services for, 528, 534
problem-based exercises, 531–534
study-based, 530–531
synopses for, 529
syntheses for, 529–530
systems for, 528–529
utility of, 527, 809
hierarchies of, 522–525, 585
impact of, 810–811
implementation of, 805–807
computers for, 807
incorporating cost-effective analysis into, 805
qualitative research on, evaluative, 599–600
explanatory, 596–599
exploratory, 587–596
steps in development of, 802–805
systematic reviews and meta-analyses for, aspirin in diabetic retinopathy, **779–792**
Cochrane Metabolism and Endocrine Disorders Review Group, **751–755**
diabetic foot care, **603–611**
glucocorticoid withdrawal schemes, **751–777**
human versus animal insulin for diabetes mellitus, **723–749**
iodized salt for iodine deficiency, **681–697**
patient education on diabetic foot ulceration, **633–658**
postmenopausal osteoporosis therapies and bone density relationship, **659–679**

thyroid disease, **793–815**
thyroid nodule pharmacotherapy, **699–721**
utility of, 527, 809
limitations of, 807–810
values and value judgments in, 569, 587, 819, 821, 823–824

Evidence-based practice. See *Evidence-based diagnosis; Evidence-based medicine.*

Exercise, excessive, uric acid nephrolithiasis with, 902

Exercise-induced amenorrhea, depression and, 67–68

Exon 2 hotspots, of *AIRE* gene, 327

Exon 10 hotspots, of *AIRE* gene, 327

Experimental autoimmune encephalomyelitis (EAE), 412, 417, 419–420

Expert consensus panels, as evidence-based practice resource, 793–799, 801, 809
organization of, 803

External review, in evidence-based practice development, 803, 805

Extracorporeal shock wave lithotripsy (ESWL), for cystinuria, 967–968, 971

F

F(ab')2 fragments, in diabetes reversal, 467

Familial hypocalciuric hypercalcemia (FHH), 144, 151

Fas ligand system, in autoimmunity, 274–275
neonatal disorders of, 290–291

Fasting, growth hormone effects of, 178
thyroid function changes with, 159, 161–162

Fasting blood glucose, with human versus animal insulin, for diabetes mellitus, 725, 729, 733, 738–744

Fasting urines, morning and night, for nephrolithiasis, 1037

Fat and fatty acids, dietary, nephrolithiasis and, hyperoxaluric, 939–940
small bowel resection impact on, 988–989

Fat metabolism. See *Obesity.*

Fatigue, 17
adrenal insufficiency and, 25–26
Cushing's syndrome and, 25

Fc receptors, in diabetes reversal, 466–469
in immunomodulatory vaccination, 446

Fear. See *Stress and stress response.*

Fear-related behaviors, stress response and, 40–41

Ferric citrate, for chronic renal failure, 112

Ferritin, in autoimmune polyglandular syndrome type II, 346, 350

Fertility, with autoimmune polyglandular syndrome type I, 316–317

Fibromyalgia (FM), hypothalamic-pituitary-adrenal axis in, 8–9
stress and pain impact on, 7–9

Fight-or-flight reaction, 79–80, 96–97

Fixed-particle theory, of nephrolithiasis, 1017–1018

Fluid intake, nephrolithiasis and, as risk factor, 1018–1019
as treatment, 1051–1052
for primary hyperoxaluric, 936–937
preventive in children, 1012
recommendations on, 1025–1026

Fluoride, in postmenopausal osteoporosis trials, 794, 804–806

Focus groups, for qualitative research, 584–585, 589–591

Follicle stimulating hormone (FSH), depression and amenorrhea similarities of, 68
hypothalamic control of, 67
in autoimmune polyglandular syndrome type II, 344, 346
major depression and, 69–70
stress response and, 65

Follicular phase, of reproduction, 65
in major depression, 68–70

Follow-up, loss to, in osteoporosis trials, 661–662

Food and Drug Administration, web site for, 532

Foot care, in diabetes, evidence-based practice, **603–611**. See also *Diabetic foot ulceration.*
abstract of, 603–604
biosynthetic dermis for noninfected foot ulcers, 607–609
off-loading of neuropathic ulcer, 607–608

Foot care, in diabetes (*continued*)
pathophysiology in, 604
preventing ulceration and amputation, 605–606
risk factors for, 604–605
synopsis of, 603, 609
systemic antibiotic therapy for noninfected ulcers, 609
systemic hyperbaric oxygen for, 609
topical growth factors for noninfected ulcers, 607–609
treatment of neuropathic ulcers, 607

Foot ulceration. See *Diabetic foot ulceration.*

Forearm, bone mineral density and fracture relationship to postmenopausal osteoporosis therapies, 666–669

Fos genes, in steroidogenesis, 196

4-S approach, to evidence-based endocrinology, 528–531, 534
problem-based examples of, 531–534

Fractures, and bone mineral density relationship to postmenopausal osteoporosis therapies, metaanalyses summary of, **659–679**
absolute differences in event rates, 666–667
background on, 659–660
bone density changes and fractures results, 669–674
bone density results, 667–669
comparison of treatment effects between, 663
management implications, 674–676
methodologic quality of studies, 660–663
nonvertebral fractures results, 665–666
vertebral fractures results, 663–665

Free water excretion, arginine vasopressin regulation of, 122–123
in edema-forming states, 124, 128
in nephrogenic diabetes insipidus, 133–135

Free-particle theory, of nephrolithiasis, 1017

Fructose, in oxalate metabolism, 930–931

Furosemide (Lasix), for hypercalcemia, 152–153
nephrolithiasis associated with, 1035–1036

G

Gallium nitrate, for hypercalcemia, 155

Gallstones, with autoimmune polyglandular syndrome type I, 309

Gastrointestinal surgery, nephrolithiasis associated with, 979–999
ammonium acid urate stones, 994–995
epidemiology of, 979–980
small bowel resection and, 985–994
total colectomy with ileostomy and, 980–984

Gastrointestinal tract, calcium absorption by, in hypercalcemia, 143–144
reduction of, 154
disorders of, autoimmune polyendocrine syndrome type I and, 300–302, 305
treatment of, 311–312
autoimmune polyendocrine syndrome type II and, 369, 380–381
diagnostic approach to, 342–343, 346–347
type 1A diabetes mellitus-associated autoimmunity and, 402–403

Gene therapy, cytokine, for immunomodulatory vaccination, 449–450

Gene-environment interactions, as type-2 diabetes mellitus etiology, **553–566**
environmental factors in, 556
evidence of, 556–557
genetic factors in, 553–556
proven examples of, 559–562
study design as binary state versus continuum, 557–558, 562
study size for detection, 559, 562

Generalizability, of evidence-based diagnosis, 579

Genetic screening, for celiac disease, 394
web-based laboratory directory of, 1012

Genetics, of autoimmune polyendocrine syndromes, animal models of, **431–439**
type 1A diabetes mellitus-associated, 392
type I, 295, 322, 335–336
type II, **353–368**, 369, 372
of autoimmune regulator (*AIRE*), **321–338**, 392
of autoimmune thyroid disease, 396–397
of autoimmunity, 275–276, 278, 412–420
disease links, 278
neonatal syndromes, 287, 289–291
type 1A diabetes mellitus-associated, 392–393, 395–397
of celiac disease, 392–395
of childhood nephrolithiasis, 1003–1007, 1012
of gonadotropin releasing hormone, 66–67
of hypercalcemia, 144, 152
of hypercalciuric nephrolithiasis, 877–880
absorptive, 877–879
mechanisms of, 874–875
other syndromes, 880
X-linked, 879–880
of immunity, acquired, 262–265
antigen processing and presentation, 267–270
HLA system, 270–274
of POMC gene expression and modification, 192–195
of primary hyperoxaluria, 932–934
of type-2 diabetes mellitus, 553–556
environment interactions with, 556
evidence of, 556–557
proven examples of, 559–562
study design considerations, 557–558, 562
of uric acid nephrolithiasis, 903–904

Gliadin, in celiac disease, 392–394

Glial cells, epinephrine toxicity and, in cardiac arrest, 93–94, 96

Glomerular filtration rate (GFR), daily, 858
in chronic renal failure, 108–109, 112–113

Glucocorticoid replacement therapy, adverse effects of, 751–752
dosage reduction with chronic disorders, 753–772
analysis methods for, 753–756
analysis results of, 757–772
discussion on, 772
indications for, 751

Glucocorticoid withdrawal schemes, in chronic medical disorders, **751–777**
clinical problem of, 751–753
systematic review of controlled trials on, 753–772
adverse effects of different schedules, 766, 772
Cochrane conclusions, 759, 764–765
data analysis, 756
data extraction form, 756
discussion on, 772
effects on acute phase of chronic disease, 759, 764–771
excluded trials, 757–758
included trials characteristics, 757, 760–763
inclusion criteria, 753–754
methods for, 753–756
outcome measures, 754, 757
quality assessment of, 756
results of, 757–772
search strategies, 754, 772, 775–777
study descriptions, 757, 759
trials selection, 754

Glucocorticoids, fibromyalgia and, 8
for autoimmune polyglandular syndrome type I, 311–312, 315
for autoimmune polyglandular syndrome type II, 348
for hypercalcemia, 155
for rheumatoid arthritis, 6–7
melancholic depression and, 48–51
obesity and, 181–182
diet effects on, 182–183
sleep effects of, 17, 25–26, 68
stress response and, 41–43, 66–67

Glucokinase abnormality, in type-2 diabetes mellitus, 554

Glucose control. See *Blood glucose*.

Glucose tolerance, Cushing's syndrome and, 200, 202
diet and weight loss effect on, 182–183

Glucose tolerance tests, in autoimmune polyendocrine syndrome type II, 344, 346, 383
in type 1 diabetes mellitus immunosuppressive therapy, 488

Glutamic acid decarboxylase (GAD), autoimmune response to, 412–413, 421, 423–425
immunomodulatory vaccination and, 442–444, 446–447

Glutamic acid decarboxylase 65 autoantibodies (GAD65Ab), in autoimmune polyendocrine syndrome type II, 369, 380, 382–383
diagnostic approach to, 343–345

Gluten-sensitive enteropathy. See *Celiac disease*.

Glycemic control, with human versus animal insulin, for diabetes mellitus, 725, 729, 733, 738–744

Glycosaminoglycans (GAGs), in hyperuricosuric calcium nephrolithiasis, 919

Glycosylated hemoglobin (Hb_{A1c}), WITH HUMAN VERSUS ANIMAL INSULIN, FOR DIABETES MELLITUS, 725, 729, 733, 738–744

Glyoxylate reductase (GR), in primary hyperoxaluria, 933–934

Glyoxylates, in oxalate metabolism, 930–931
childhood, 1006
molecular pathophysiology of, 932–934

Goiter. See also *Iodine deficiency*.
iodized salt prevention of, 683, 690–693

Gonadal steroids, in hypercalcemia, 145–148

Gonadotropin(s), chronic renal failure and, 116–117
hypothalamic control of, 67

Gonadotropin releasing hormone (GnRH), depression and amenorrhea similarities of, 68
hypothalamic control of, 67
major depression and, 69–70
premenstrual mood disorders and, 71–72
stress response and, 65–67

Gout, primary, calcium oxalate stones and, 920–921
uric acid nephrolithiasis with, 903

Gouty diathesis, uric acid nephrolithiasis with, 904, 908

Graftskin, for noninfected diabetic foot ulcers, 607–609

Graft-versus-host disease (GVHD), glucocorticoid therapy withdrawal analysis, 760, 765, 767, 770

Granulocyte colony-stimulating factor (G-CSF), in neonatal immune system, 283–284

Granulomatous disease, central diabetes insipidus associated with, 129–132
hypercalcemia in, 142, 151

Graves' disease, autoimmune polyendocrine syndrome type II and, 370–371, 373–376
autoantibody specifics of, 379, 381–382
clinical aspects of, 341–342
treatment of, 348–349
genetics of, 396–397
in neonates, 289–290
type 1A diabetes mellitus-associated autoimmunity and, 396

Growth factors, hypercalcemia and, 143–149, 151
topical, for noninfected diabetic foot ulcers, 607–609

Growth hormone, anorexia nervosa effect on, 178–179, 185
obesity effect on, 177–178, 185
weight loss and, 178

Growth hormone-releasing hormone (GHRH), anorexia nervosa effect on, 178
obesity effect on, 177–178

Guideline development, for endocrinology practice. See *Clinical practice guidelines*.

Guideline development panel, in evidence-based practice development, expert consensus, 587, 793–799, 801, 803, 809
organization of, 803

H

Hashimoto's thyroiditis. See *Autoimmune thyroid disease (AITD)*.

Head and neck cancer, syndrome of inappropriate antidiuretic hormone secretion associated with, 125

Head trauma, epinephrine response to, 84

Health care costs, clinical practice guidelines impact on, 810–811

Health care policy, clinical practice guidelines impact on, 810–811

Health education, clinical practice guidelines impact on, 810
for diabetic foot ulceration prevention. See *Patient education.*
qualitative research on, evaluative, 599–600
explanatory, 596–599
exploratory, 586, 595–596

Heart disease, chronic renal failure and, 111, 117
epinephrine toxicity and, 87–89
with acute severe stress, 86–87
with cardiac arrest, 89–97
evidence-based diagnosis of, 569, 578, 580
interventions for, evidence-based medicine example, 523
qualitative research on, 598–600
melancholic depression and, 39, 52–53
nonthyroidal illness syndrome and, 161, 166

Heart Outcomes Prevention Evaluation (HOPE) study, of diabetes with albuminuria, baseline measurements and risk factors, 541
data analysis, 543–1267
design of, 538–539
population selection, 539–540

Helicobacter pylori, type 1A diabetes mellitus-associated autoimmunity and, 402

Helper T-cell subsets. See *T-helper (Th) subtypes.*

Hematuria, with childhood hypercalciuria, 1002–1003, 5956

Hemodialysis (HD), for chronic renal failure, phosphorus and calcium homeostasis in, 108–111
management of, 111–114

Hemoglobin, glycosylated, with human versus animal insulin, for diabetes mellitus, 725, 729, 733, 738–744
glycosylated (HbA1c), in type 1 diabetes mellitus immunosuppressive therapy, 482, 490

Hepatitis, autoimmune, autoimmune polyendocrine syndrome type I and, 302–303
diagnostic approach to, 309
treatment of, 311–312

Heterogenous nucleation, in urine supersaturation, 859–860
regulation of, 861–862

Hierarchy of evidence, benefit versus risk trade-off in, 823–825
in evidence-based medicine, 522–525, 824
in qualitative research, 585

Hip, bone mineral density and fracture relationship to postmenopausal osteoporosis therapies, 660, 666–669

Hippocampus, obesity and, 181–182

H+/K+-ATPase autoantibodies, in autoimmune polyendocrine syndrome type II, 369, 381–382, 384
in type 1A diabetes mellitus-associated autoimmunity, 403

HLA genes, nomenclature for, 271–272, 276

Homogeneously staining region (HSR), of *AIRE* gene, 329, 334–335

Hormone(s). See also *specific hormone, e.g., Thyroid hormone(s).*
acute severe stress and, 80, 83
chronic renal failure and, 112, 114
hypercalcemia and, 143–149
obesity and starvation effects on, **173–189**

Hormone replacement therapy, for autoimmune polyglandular syndrome type II, 347–349
in postmenopausal osteoporosis trials, 661–18

Human immunodeficiency virus (HIV) infection, thyroid function changes with, 163–164

Human leukocyte antigen (HLA), immunology of, 270–274
lymphocyte development and, 273–274
MHC class I chain related genes and, 272–273
nomenclature for, 271–272
in Addison's disease, 398–399
in autoimmune polyglandular syndrome type II, 354–356, 358–361, 363–364
animal models of, 433
autoantibodies and, 370, 379
MICA-A polymorphism and, 361–362
in autoimmune thyroid disease, 396–397
in celiac disease, 392–396
in congenital rubella syndrome, 401–402
in juvenile rheumatoid arthritis, 401
in multiple sclerosis, 400–401

Human leukocyte (*continued*)
in neonatal polyendocrinopathy syndromes, 289
peripheral antigen-expressing cells and, 419

"Humor," malignant, in osteoclast stimulation, 150

"Hungry bone" syndrome, 111

Hydration. See *Volume expansion.*

Hydrocortisone, for autoimmune polyglandular syndrome type II, 348

17α-Hydroxylase autoantibodies, in autoimmune polyendocrine syndrome type II, 369, 376–378, 383

21-Hydroxylase autoantibodies, in Addison's disease, 398
in autoimmune polyendocrine syndrome type II, 369–373
clinical applications of, 382–384

Hydroxyproline, in oxalate metabolism, 930–931

Hydroxypyruvated reductase (HPR), in primary hyperoxaluria, 933–934

17-Hydroxysteroids, excretion of, in sleep disorders, 19, 21

3-β-Hydroxysteroid-dehydrogenase autoantibodies (3βHSDAb), in autoimmune polyendocrine syndrome type II, 378

Hyperbaric oxygen, systemic, for diabetic foot ulcers, 609

Hypercalcemia, **141–158**
autoimmune polyendocrine syndrome type I and, 313–315
clinical manifestations of, 143–144
differential diagnosis of, 141–143
diseases associated with, 149–152
endocrine disorders and, 142
genetics of, 144, 152
granulomatous disease and, 142, 151
immobilization and, 142, 151–152, 155–156
malignancies and, 141, 150–151
metabolic disorder and, 142
nephrogenic diabetes insipidus associated with, 129, 133–134
osteoclast bone resorption in, 143–147, 151
inhibition of, 152–154
pathophysiologic mechanisms of, 143–149
primary hyperparathyroidism and, 149
renal disease and, 141, 143–144, 151
treatment of, 152–153
treatment of, 144, 152
bone resorption inhibition as, 144, 153
calcium absorption reduction as, 154
calciuresis as, 144, 153
glucocorticoids as, 155
miscellaneous, 155–156
underlying disease in, 144, 154–155
volume expansion as, 144, 153

Hypercalciuria, dietetic factors of, 1052–1054
drug therapy for, 1054–1056
genetics of, 1003–1006
idiopathic childhood, nephrolithiasis with, 1002–1003, 1010–1012
pathogenesis of, 869–871

Hypercalciuric nephrolithiasis, **869–884**
genetics of, 877–880
absorptive, 877–879
other syndromes, 880
X-linked, 879–880
historical view, 869
hyperoxaluric, 927–943
hypocitraturic, 885–891
mechanisms of, 872–877
absorptive, 873–874, 1021
acquired, 875–876
genetic, 874–875
renal, 873, 877
resorptive, 873, 877
normal calcium homeostasis, 871–872
pathogenetic role of calcium, 869–871

Hypercapnia, syndrome of inappropriate antidiuretic hormone secretion associated with, 127

Hypercortisolism, anorexia nervosa and, 183–184
corticotropin-dependent, 196–197
diagnosis of, 207–209
differential diagnosis of, 209
ectopic proopiomelanocortin syndrome and, 205–214
major depression and, 66, 70
atypical correlations, 54–55
melancholic correlations, 48–51
obesity and, 180–181

Hyperoxaluria, dietetic factors of, 1052–1054
drug therapy for, 1056–1057
enteric, 939–940
small bowel resection association with, 985–986
treatment of, 990–994

Hyperoxaluric calcium nephrolithiasis, **927–949**
diet factors of, 940–943
enteric, 939–940
small bowel resection and, 985–986
treatment of, 990–994
overview of, 927–928, 943
oxalate metabolism and, 928–932
endogenous, 930–931
intestinal, 928–930
renal excretion, 931–932
primary, 932–939
clinical course of, 934–936
medical therapy for, 936–937
molecular pathophysiology of, 932–934
transplantation for, 936, 938–939

Hyperparathyroidism, primary,
hypercalcemia in, 149
secondary in renal failure,
management of, 111–114
pathophysiology of, 108–111

Hyperphagia, atypical depression and, 54–55

Hyperphosphatemia, chronic renal failure and, pathophysiology of, 108–111
prevention of, 111–114

Hyperprolactinemia, chronic renal failure and, 116–117

Hypersomnia, idiopathic, 17, 25
cytokines and, 29

Hypertension, Cushing's syndrome and, 200, 202
in primary aldosteronism screening, 621–622, 628

Hyperthyroidism, autoimmune, 397
evidence-based clinical practice guidelines for. See *Thyroid disease*.
in neonates, 289–290
nonthyroidal illness syndrome and, 163, 166–168

Hyperuricosuria, dietetic factors of, 917, 1052–1054
drug therapy for, 1057–1058
gout and, 920–921
metabolic definition of, 916–917
pathophysiology of, 920
uric acid nephrolithiasis and, 901–903

Hyperuricosuric calcium nephrolithiasis (HCN), **915–925**
age and sex differences in, 917
calcium stones and, 920–921
clinical presentation, 916
definition of, 915
medical management of, 921–922
metabolic abnormalities, 916–917
pathophysiology of, 901–903
physiochemistry, 917–920
calcium oxalate solubility and, 919–920
crystallography in, 918–919
inhibitor studies, 919
renal tubule blockage, 920
radiographic findings, 916
stone analysis, 915–916
surgical management of, 922–923

Hypocalcemia, autoimmune polyendocrine syndrome type I and, 300–301
diagnostic approach to, 307, 309–310
treatment of, 310, 312–315

Hypocitraturia, dietetic factors of, 1052–1054
drug therapy for, 891, 1058–1059
with small bowel resection, 985

Hypocitraturic nephrolithiasis, **885–893**
age and sex differences in, 888–889
causes of, 889–891
childhood, 1009
citrate metabolism and, 885–888
acid-base parameters effect on, 888
pathogenic, 889–891
in proximal tubule, 887–888
kidney reabsorption, 886
molecular mechanisms of transport, 887
other regulators of, 888
overall, 885–886
tubule transport, 886–887
epidemiology of, 888–889
management of, 891
pathogenesis of, 889–891

Hypoglycemia, insulin-induced, for rheumatoid arthritis, 6
with human versus animal insulin, for diabetes mellitus, 729, 733, 738–744

Hypogonadism, autoimmune polyendocrine syndrome type I and, 298
diagnostic approach to, 306, 308
prognosis of, 316–317
treatment of, 311–312
autoimmune polyendocrine syndrome type II and, 370–371
diagnostic approach to, 343–344, 346

Hypogonadism, autoimmune (*continued*)
steroid-producing cell autoantibodies and, 376–378
treatment of, 349

Hypokalemia, nephrogenic diabetes insipidus associated with, 129, 134–135

Hypomagnesemia, autoimmune polyendocrine syndrome type I and, 313

Hypomagnesuria, with small bowel resection, 985, 993–994

Hyponatremia, hypoosmolar, disorders associated with, 124, 128
in water homeostasis, 123, 126

Hypoparathyroidism, autoimmune polyglandular syndrome type I and, 295, 298, 302–304
diagnostic approach to, 306–309
prognosis of, 316–317
treatment of, 310–314

Hypopituitarism, central diabetes insipidus associated with, 130–131

Hypotension, in water homeostasis, 122

Hypothalamic amenorrhea, depression and, 67–68

Hypothalamic-pituitary-adrenal (HPA) axis, major depression and, 48–49, 51, 64
amenorrhea similarities in, 67–68
atypical, 53–55
neuroendocrine-immune regulatory loop in, 1–3
obesity and, Cushing's syndrome versus, 181–182
diet effects on, 182–183
obesity effects on, 179–181
rheumatic diseases and, **1–13**
animal models of, 3–5, 8
arthritis and, 5–7
fibromyalgia and, 8–9
stress and pain impact on, 7–9
physiology of, 1–3
Sjögren's syndrome and, 7
systemic lupus erythematous and, 4–5, 7
sleep and, **15–36**
age impact on, 20
cytokine impact on, 26–31
disordered/disturbed physiology of, 21–26
normal physiology of, 17–21
sleep deprivation impact on, 20–21
stress response and, 41–44, 64–67, 80–82
stress-induced analgesia and, 8
suppression of, with glucocorticoid therapy, 752–753
weight loss effects on, 182–183

Hypothalamic-pituitary-gonadal (HPG) axis, feedback function of, 65
mood disorders and, **63–78**
amenorrhea and depression similarities, 67–68
gender-based depression rate differences, 63–64
gonadotropin control, 67
ovarian steroids and depression in, 72–73
premenstrual syndrome and ovarian hormones, 71–72
reproductive hormones and depression, 68–70
stress and reproductive axis, 65–67

Hypothalamic-pituitary-thyroid (HPT) axis, anorexia nervosa and, 176–177
nonthyroidal illness syndrome and, changes in, 162–163
physiology of, 159–160
obesity and, 174–175

Hypothalamus, epinephrine toxicity and, in cardiac arrest, 91–93
gonadotropin control by, 67
plasma osmolality regulation by, 122–123, 127

Hypotheses generation, in qualitative research, 585–587
on Bangladeshi diabetes health beliefs, 587–596
background on, 587–588
methods for, 588–594
results analysis, 594–596

Hypotheses testing, in quantitative research, 585–587

Hypothyroidism, anorexia nervosa and, 177
evidence-based clinical practice guidelines for. See *Thyroid disease*.
nonthyroidal illness syndrome and, 162, 166–168

Hypouricemia, childhood nephrolithiasis with, 1009

Hypoxemia, syndrome of inappropriate antidiuretic hormone secretion associated with, 127

I

IA-2, autoimmune response to, 412–413
self-molecule expression with, 418–419, 421, 424–425

ICAM-1 signaling pathway, in co-stimulation response, 265

IDDM2 expression, in autoimmunity, 416

Idiopathic hypersomnia, 17, 25
cytokines and, 29

Idiopathic uric acid nephrolithiasis, 904–908
in children, 1002–1003, 1010–1012

IgA, in type 1A diabetes mellitus-associated autoimmunity, 399–400

Ignorance, in immunology, 276

Ileal pouch anal anastomosis, uric acid stone formation with, 982

Ileal resection. See *Small bowel resection.*

Ileostomy, total colectomy with, nephrolithiasis associated with, 980–984
calcium stones, 983–985
etiology, 983–984
treatment, 984
uric acid stones, 980–983
etiology, 980–982
treatment, 982–983

Imaging studies, for ectopic proopiomelanocortin syndrome, 214–216

Imipramine, for major depression, ovarian steroids' influence on, 72–73

Immobilization, hypercalcemia with, 142, 151–152, 155–156

Immunity. See *Autoimmunity; Immunology.*

Immunoblotting, for autoimmune polyendocrine syndrome type II, 378

Immunocytochemistry, for *AIRE* protein, 323–325

Immunofluorescence tests, for autoimmune polyendocrine syndrome type II, 370–371, 378, 380
of peripheral antigen-expressing cells, 421–422, 425

Immunoglobulins, antigen recognition by, 262–265
B-cell source of, 263
IgA, in type 1A diabetes mellitus-associated autoimmunity, 399–400
in neonatal autoimmunity, 275

Immunologic vaccines, autoimmune disease and, 442–443

Immunology, **261–282**
acquired, B-lymphocytes and antigen recognition, 262–264
features of, 261–262
helper T-cell subsets in, 265, 277
lymphocyte activation in, 266–267, 461
T-lymphocytes and antigen recognition, 264–265
adaptive, 285–286
antigen processing/presentation in, 267–270
class I pathway, 267–269
class II pathway, 269–270
co-stimulation signals, 461
autoimmune mechanisms in, 274–279. See also *Autoimmunity.*
components of system, 261–262
genetics of, acquired, 262–265
antigen processing and presentation, 267–270
HLA system, 270–274
human leukocyte antigen system in, 270–274
lymphocyte development and, 273–274
MHC class I chain related genes and, 272–273
nomenclature for, 271–272
in neonates, adaptive versus innate, 283–286
autoimmune syndromes of, 286–291
innate, 261, 283–285
introduction to, 261–262, 279
tolerance in, 274–276, 412, 417

Immunomodulatory vaccination, in autoimmune disease, **441–456**
anti-CD3 antibody treatment and, 451
autoimmune polyendocrine syndromes, 442
controversial effects of, 448–449
cytokines role, 443–445, 449–450
dendritic cell vectors and, 450–451
DNA vaccines, 445–449
immunologic vaccines, 442–443
NOD mouse, 442
peptide/protein vaccines, 443–445, 448–449
trends and conclusions, 441, 452

Immunostimulants, in type-1 diabetes mellitus intervention trial, 483–484

Immunosuppressive therapy, for
autoimmune polyglandular syndrome type I, 311–312
for autoimmunity, 278–279
for type 1 diabetes mellitus, **477–495**
early prevention attempts, 481–482
glucose control trials, 482
indications for use, 477–479
introduction to, 477, 491
prevention trials design issues, 488–490
prevention trials enrollment, 479–481
recent intervention trials, 482–488
trial results, 485–486

Indapamide, for hypercalciuria, 1054–1055

Infection-related nephrolithiasis, 1041
childhood, 1008–1009

Infectious disease(s), sleep disorders with, 26
syndrome of inappropriate antidiuretic hormone secretion associated with, 124, 126–127

Inferior petrosal sinus sampling (IPSS), for ectopic Cushing's syndrome, 212–214

Infertility, chronic renal failure and, 116–117

Inflammatory bowel disease, nephrolithiasis from, 979, 982, 986
surgery associated with. See *Small bowel resection; Total colectomy.*

Inflammatory disease(s), central diabetes insipidus associated with, 129–131
hypercalcemia in, **141–158**
sleep disorders and, 26–31
syndrome of inappropriate antidiuretic hormone secretion associated with, 124, 126–127

Information system(s), as evidence-based endocrinology resource, 528–529

Informed consent, for qualitative research, 589

Inhibitor proteins, in nephrolithiasis. See *Crystallization inhibitors.*

Innate immunology, 261, 283–285

In-situ hybridization, of *AIRE* protein, 324–325

Insomnia, cortisol production and, 21–24
cytokines and, 31
glucocorticoids and, 20
hypothalamic-pituitary-adrenal axis and, 21–22

Institute for Clinical Systems Improvement, in diabetes mellitus practice guidelines review, 818

Institute of Medicine, in diabetes mellitus practice guidelines review, 818–819

Insulin, autoimmune response to, 412–413
self-molecule expression with, 413, 416–417
thymic expression and, 276–277
human versus animal for diabetes mellitus, systematic review of, **723–749**
background on, 724–725
crossover studies, 729, 733, 740–743
data analysis, 727–728
data extraction form, 727
discussion on, 744–745
excluded trials, 726
hypoglycemic episode results, 729, 733, 738–744
included trials characteristics, 728–732, 734–737
inclusion criteria, 725
insulin antibodies results, 729, 733, 738–744
insulin dose results, 729, 733, 738–744
metabolic control results, 729, 733, 738–744
methods for, 725–727
outcome measures, 725–726
parallel studies, 729, 733, 738–739
quality assessment of, 726–727
results analysis, 728–729, 738–744
results summary, 723–724
search strategies, 726
trials selection, 726
role in ammonia excretion, 901

Insulin antibodies, with human versus animal insulin, for diabetes mellitus, 729, 733, 738–744

Insulin autoantibodies (IAA), in autoimmune polyendocrine syndrome type II, 380, 382
diagnostic approach to, 343–345

Insulin deficiency, neonatal autoimmune, 287–289

Insulin dose, of human versus animal insulin, for diabetes mellitus, 729, 733, 738–744

Insulin gene expression, autoimmunity and, 276–277

Insulin resistance, idiopathic uric acid nephrolithiasis and, 904–908
  treatment of, 909
  melancholic depression and, 39, 52
  with obesity, 180–181

Insulin-dependent diabetes mellitus (IDDM). See *Type-1 diabetes mellitus (T1DM)*.

Insulin-induced hypoglycemia, for rheumatoid arthritis, 6

Insulin-like growth factor (IGF-1), obesity effect on, 177–178
  weight loss and, 178

Insulin-like growth factor 2 (IGF2), polymorphisms of, in type-2 diabetes mellitus, 559, 561

Insulin-like growth factor-binding protein 1 (IGFBP1), polymorphisms of, in type-2 diabetes mellitus, 559, 561

Intention-to-treat, in osteoporosis trials, 661–662

Interferon, hypercalcemia and, 145–147, 149, 151
  in immunomodulatory vaccination, 443–444, 446, 448–449
  neuroendocrine-immune regulatory loop and, 2–3

Interleukins (IL), atypical depression and, 55
  autoimmune polyglandular syndromes and, 436
  chronic renal failure and, as bone resorption marker, 112
  hypercalcemia and, 145–147, 151
  immunomodulatory vaccination and, 444, 446, 448–451
  in autoimmunity, helper T-cell subset source of, 265, 277
  in neonatal immune system, 285–286
  lymphocyte activation and, 266–267, 461
  neuroendocrine-immune regulatory loop and, 1–3
    animal models of, 4
  nonthyroidal illness syndrome and, 165
  rheumatoid arthritis and, 5–6
  sleep disorders and, 26–29, 31
  systemic lupus erythematosus and, 7
  type 1 diabetes mellitus
    immunosuppressive therapy and, 479, 484–485, 487

International Council for Control of Iodine Deficiency Disorders (ICCIDD), on iodized salt for iodine deficiency review, 682–683, 685

Internet resources, for evidence-based medicine, 528–531, 807–808
  limitations of, 824–825

Intervention trials. See also *Clinical trials*, on diabetes mellitus, evaluative qualitative research in, 599–600
  explanatory qualitative research in, 596–599
  exploratory qualitative research in, 587–596

Interviews, for qualitative research, 584, 589–591, 595

Intestinal disease. See *Bowel disease*.

Intestinal metabolism, of oxalate, 928–930, 987
  alterations with bowel resection, 987–989

Iodine deficiency, systematic review of iodized salt for, **681–697**
  clinical problem of, 681
  data analysis, 686
  data extraction form, 685–686
  discussion on, 691, 694
  excluded trials, 686–687
  history of prevention of, 682
  included trials characteristics, 686, 688–690
  inclusion criteria, 683–684
  intervention effects, 690–693
  interventions and compliance assessment, 687, 690
  outcome measures, 684, 687, 690
  quality assessment of, 685
  research evidence review, 683
  results of, 686–691
  search strategies, 684–686
  supplementation programs, 682–683
  trials selection, 685

Iodized salt, for iodine deficiency prevention, background on, 681–683
  potassium iodate versus potassium iodide, 682–683, 690–694
  systematic review of, 681–697
    discussion on, 691–694
    methods for, 681–686
    results of, 686–691

Iodothyronine deiodinases, nonthyroidal illness syndrome and, 160, 164
overexpression of type 3, 165

Ion-activity products, with nephrolithiasis, 1031–1033
calcium stones, 1038–1040
crystalluria versus, 862–863
cystine stones, 1040–1041
infectious stones, 1041
normal limits of formation and urine variables of, 1041–1042
solubility and, 856–857

IPEX/XLAAD/XPID syndrome, in neonates, 287–289

Iron deficiency anemia, autoimmune polyglandular syndrome type II and, 342, 346, 350

Irrigation solutions, for struvite calculi, 971

Islet cell tumors, pancreatic, ectopic proopiomelanocortin syndrome and, 198, 203–204

Islet-cell antibodies (ICA), in autoimmune polyendocrine syndrome type II, 369, 378, 380, 382–383
diagnostic approach to, 343–345
in autoimmunity, 412, 436
type 1A diabetes mellitus-associated, 391, 401–402
CD3 antibodies and, 469
cytoplasmic expression of, 483–484, 489
immunomodulatory vaccination and, 442, 444
immunosuppressive therapy for, 478, 480–481
in neonatal polyendocrinopathy syndromes, 288

Islet-cell transplantation, for type 1 diabetes mellitus, 478, 481, 484–485

J

Jejunoileal bypass (JIB), nephrolithiasis associated with, 986–987

Jun genes, in steroidogenesis, 196

Juvenile rheumatoid arthritis (JRA), type 1A diabetes mellitus-associated autoimmunity and, 401

K

Kabuki syndrome, in neonates, 291

Keratoconjunctivitis, autoimmune polyendocrine syndrome type I and, 304–305, 381
treatment of, 315

Kidney(s), metabolic role of. See *Renal excretion.*

Kidney stones. See *Nephrolithiasis.*

Kidney transplantation, primary hyperoxaluria and, 936

Kidneys, autoimmune polyendocrine syndrome type I and, 303, 305
calciferol replacement therapy and, 313–314

Knowledge Finder (KF), as evidence-based medicine resource, 530

Kreb's cycle, citrate as central component of, 886–888

KUB abdominal radiography, for nephrolithiasis analysis, 916, 1033–1034

L

Laboratory screening directory, web-based, for genetic disorders, 1012

Laboratory tests, serum. See *Blood tests.*
urine. See *Urine analysis.*

Lactic acidosis, with epinephrine toxicity, 87–88

Langerhans cell histiocytosis (LCH), central diabetes insipidus associated with, 129, 132–133

Language, as qualitative research factor, 589, 591

Laser lithotripsy, with percutaneous nephrostolithotomy, 1070–1071
with ureteroscopy, 1072

Late luteal phase disorder, ovarian hormones in, 71–72

Latent autoimmune diabetes in adults (LADA), endocrinopathy risks with, 380, 383

Lay informants, in qualitative research, 595–596

Left ventricular hypertrophy, chronic renal failure and, 115–116

Leptin, sleep apnea and, 28–29

Leukocytes, in neonatal immune system, 283–284

Leukoencephalopathy, autoimmune polyendocrine syndrome type I and, 305

Leuprolide, for premenstrual mood disorders, 71–72

Levothyroxine. See *Thyroxine suppressive therapy*.

LFA-1 signaling pathway, in co-stimulation response, 265

Libido, chronic renal failure and, 116–117

Life-threatening situations. See *Stress and stress response*.

Likelihood ratios (LRs), in evidence-based diagnosis, 574–577, 579
  calculation of, 580–581
  clinical examples of, 623

Lilacs search, in iodized salt for iodine deficiency review, 684, 686

Linkage disequilibrium (LD) analyses, of autoimmune polyendocrine syndrome type II, 356, 358, 364

Lipopolysaccharide (LPS), in immunology, 261

Liquid intake, as nephrolithiasis treatment, 1051–1052

Literature reviews, conventional narrative, as evidence-based practice resource, 795–799
  systematic. See *Systematic literature reviews*.

Lithium, hypercalcemia and, 144, 151–152

Lithotomy, open, for hyperuricosuric calcium nephrolithiasis, 922–923
  for urolithiasis, 1072–1073

Lithotripsy, 1069–1070
  electrohydraulic, 1070–1072
  laser, 1070–1072
  percutaneous. See *Percutaneous nephrolithotomy*.
  pneumatic, 1069–1070
  shock wave. See *Shock wave lithotripsy (SWL)*.
  ultrasonic, 1068–1069

Liver biopsy, for primary hyperoxaluria, 935

Liver transplantation, for primary hyperoxaluria, 938–939

Locus ceruleus-norepinephrine (LC-NE) system, as core stress component, 41, 45
  in Cushing's syndrome versus obesity, 181
  major depression and, 47–48

Loop of Henle, in urine crystallization, 858, 861–862
  thick ascending limb of, in nephrogenic diabetes insipidus, 133–135

Loss to follow-up, in osteoporosis trials, 661–662

Low T3 syndrome, nonthyroidal illness and, 160–161

Low thyroxinellow triiodothyronine syndrome, nonthyroidal illness and, 161–162

Lower extremity amputation, diabetes mellitus and, 603–606, 609
  prevention of. See *Diabetic foot ulceration*.

Lumbar spine, bone mineral density and fracture relationship to postmenopausal osteoporosis therapies, 667–669

Luteal phase, of reproduction, 65
  late disorder of, 71–72
  major depression and, 68–70

Luteinizing hormone (LH), autoimmune polyglandular syndrome type II and, 344, 346
  hypothalamic control of, 67
  major depression and, 68–70
    amenorrhea similarities of, 68
  stress response and, 65–67

Lymphocyte(s), in autoimmunity, 411–412
  in immunology. See also *B-lymphocytes*; *T-lymphocytes*.
    acquired activation of, 266–267, 461
    antigen recognition and, 458–460
    HLA and development of, 273–274
    neonatal, 285–286

Lymphocyte receptors, in self-tolerance restoration, 458–460

Lymphoid system, in autoimmunity, 411–412
  animal models of, 434–435
  self-molecule expression and, 412–415
    cells involved in, 420–425
  tolerance and, 274–276, 412, 417

Lysine, in cystinuria pathology, 951–953
  molecular basis of, 953–960

M

Macrophage inhibitory factor (MIF), neuroendocrine-immune regulatory loop and, 3

Macrophages, in autoimmunity, 323, 425
in immunology, 261, 457
in neonatal polyendocrinopathy syndromes, 283, 285
in type 1 diabetes mellitus immunosuppressive therapy, 478, 480

Magnesium balance, small bowel resection impact on, 985, 993–994

Magnesium citrate, for childhood nephrolithiasis, 1012–1013
for hypocitraturia, 891

Magnesium hydroxide, for hyperoxaluria, 1056–1057

Magnesium oxide, for primary hyperoxaluric, 937

Magnetic resonance imaging (MRI), for ectopic Cushing's syndrome, 214–215

Major depression. See *Depression.*

Major histocompatibility complex (MHC), autoimmune polyglandular syndrome type II and, 358–361, 364, 435
in autoimmunity, 411–412, 417, 420
in immunology, antigen recognition and, 262–263, 265
class I chain related genes and, 272–273
class I pathway of, 267–269
class II pathway of, 269–270
co-stimulation signals, 461
HLA system of, 270–274
lymphocyte activation and, 266

Malignancy(ies), hypercalcemia in, 141, 150–151

Malnutrition. See also *Anorexia nervosa.*
hormone secretion effects of, **173–189**
hypothyroidism and, 177
thyroid function, 176–177

Matrix calculi, 972

Maturity onset diabetes of the young (MODY), genetics of, 554

Measurement validity, in qualitative research, 584, 592–594

Mechanical ventilation, syndrome of inappropriate antidiuretic hormone secretion associated with, 124, 128

Medical disorders, chronic. See *Chronic medical disorders.*

MEDLINE, as evidence-based medicine resource, 529–530, 614, 616
in aspirin for diabetic retinopathy review, 783, 791–792
in diabetes mellitus foot care, 605, 607
in diabetes mellitus practice guidelines review, 636, 818
in glucocorticoid withdrawal schemes review, 754, 757, 772, 775–776
in human versus animal insulin review, 726, 728, 747–749
in iodized salt for iodine deficiency review, 684, 686, 696–697
in primary aldosteronism screening review, 620
in thyroid nodule pharmacotherapy review, 702, 719
problem-based examples of, 532–534

Medroxyprogesterone acetate (MPA), leuprolide administration and, 72

Megaloblastic anemia, autoimmune polyglandular syndrome type II and, 342, 346

Melancholic depression, as clinical syndrome, 38–40
long-term medical consequences of, 37, 52–53
pathophysiology of, 47–52
stress response and, 37, 40–46

Menstrual cycle, depression and, 67–68
disorders of, chronic renal failure and, 116–117
hypothalmic-pituitary-gonadal axis regulation of, 65–67
major depression and, 68–70

MeSH-terms, as search strategy. See *MEDLINE.*

Messenger RNA (mRNA), Nur77, in POMC gene transcription, 192–194

Metaanalyses, by Cochrane Library, 616–617
of glucocorticoid withdrawal schemes, 756, 777
of human versus animal insulin for diabetes mellitus, 727, 748–749
of iodized salt for iodine deficiency, 683
of postmenopausal osteoporosis therapies and bone density

relationship, **659–679**
of thyroid nodule pharmacotherapy, 701–702, 720–721

Metabolic control, with human versus animal insulin, for diabetes mellitus, 725, 729, 733, 738–744

Metabolic defects, in childhood nephrolithiasis, 1007–1008
in primary hyperoxaluria, 932–934

Metabolic disorder(s), epinephrine toxicity and, 87–88
hypercalcemia with, 142
nephrogenic diabetes insipidus associated with, 129, 133–135

Metabolic syndrome, uric acid nephrolithiasis with, 904–908
treatment of, 909

Methionine, for cystinuria, 965

Metyrapone test, for ectopic Cushing's syndrome, 210–211

MHC genes, class I chain related, 272–273

MIC genes, in immunology, 273

MICA-A molecule, in autoimmune polyglandular syndrome type II, 361–362

Microalbuminuria, with diabetes mellitus, as evidence-based diagnosis, 567–570, 575, 579
cardiovascular event risks with, **537–551**
categorical variables of, 540–541
characteristics of, 540–541
continuous variables of, 540–541
date collection over time versus at point in time, 542–543
epidemiologic establishment of, 539
etiology and pathogenesis implications of, 546–547
HOPE study baseline measurements and factors, 541
HOPE study data analysis, 543–1267
HOPE study design, 538–539
HOPE study population, 539–540
measurements, exposures, and factors of, 540–541
outcome constructions, 541–542
population characterization, 539
progressive variables of, 541
scope of, 537–538, 548–550
statistical expression of, 545–546
therapy implications of, 548–549

Microalbuminuria, Cardiovascular and Renal Outcomes (MICRO HOPE) study, 538, 543, 547

Microaneurysm, with aspirin for diabetic retinopathy, 786, 788–789

Microneurography, of sleep disorders, 25

Mineralocorticoids, for autoimmune polyglandular syndrome type II, 348

Mixed uremic osteodystrophy, 110–111, 114

Molecular pathophysiology. See *Genetics*.

Molecular transport, of citrate, 887

Monoamine oxidase (MAO) inhibitors, major depression and, 47–48, 51

Monoclonal antibodies, depleting mechanisms of, 461–463
for self-tolerance restoration, **457–475**
CD3 antibodies and, 458–460, 466–469
diabetes relevance, 465–466
diabetes reversal with, 466–467
introduction to, 457–458, 469–470
mode of action, 461–464
receptor specificities, 458–461
tolerogenic properties of, 464–465
nondepleting mechanisms of, 463
therapeutic, 459

Mood disorder(s), hypothalamic pituitary gonadal axis in, **63–78**
amenorrhea and depression similarities, 67–68
gender-based depression rate differences, 63–64
gonadotropin control, 67
ovarian steroids and depression in, 72–73
premenstrual syndrome and ovarian hormones, 71–72
reproductive hormones and depression, 68–70
stress and reproductive axis, 65–67

Morbidity, as evidence-based medicine factor, 615
in chronic renal failure, 107–108, 117

Morphine tolerance, adrenocorticotropic hormone and, 8

Mortality, as evidence-based medicine factor, 615
in chronic renal failure, 107–108, 117

Mouse models, diabetic. See *Nonobese diabetic (NOD) mouse model.*
of AIRE protein, 323–324
of autoimmune polyglandular syndromes, type I, 432
type II, 434
type IV, 435–437
of autoimmunity, 275–276
peripheral antigen-expressing cells in, 411, 414–415, 420–421, 423–424
of monoclonal antibodies, in autoimmune diabetes, 465–467
in self-tolerance restoration, 464–465
of rheumatic diseases, 3–5, 8
of T-lymphocyte development, 274

Multiple sclerosis, glucocorticoid therapy withdrawal analysis, 764
immunomodulatory vaccination and, 447
type 1A diabetes mellitus-associated autoimmunity and, 400–401

Munchausen's syndrome, childhood nephrolithiasis and, 1009

Musculoskeletal pain, fibromyalgia and, 7–8

Mycophenolate mofetil (MMF), in type-1 diabetes mellitus intervention trial, 486–487

Myelin basic protein (MBP), autoimmune response to, 412–413
self-molecule expression with, 417–418
in multiple sclerosis, 401

Myelin glycoproteins, in multiple sclerosis, 400–401

Myelin proteolipid protein, in autoimmune response, 412, 419–420
in multiple sclerosis, 400–401

N

Na^+/H^+ exchanger 3 (NHE3), in ammonia excretion, 900–901

Na-inorganic phosphate cotransporter 1 (NPT1), in uric acid excretion, 899–900

Narcolepsy, 17, 25
cytokines and, 29

Narrative. See *Storytelling.*

Narrative literature reviews, conventional, as evidence-based practice resource, 795–799

National Guidelines Clearinghouse, in diabetes mellitus practice guidelines review, 818

National Institutes of Health (NIH), consensus development by, 795, 806

Natural killer (NK) lymphocytes, in autoimmunity, 277
in immunology, 261, 265
in polyendocrinopathy syndromes, neonatal, 283, 285
type II, 378

Negative predictive value (NPV), in evidence-based diagnosis, 573–574

Neonates, autoimmune syndromes of, 286–291
lymphoproliferative, 290–291
Di George syndrome in, 290
hyperthyroidism in, 289–290
immune system of, adaptive, 285–286
innate, 283–285
IPEX/XLAAD/XPID syndrome in, 287–289
Kabuki syndrome in, 291
polyendocrinopathy of, **283–293**
adaptive immune response and, 285–286
innate immune system and, 283–285
syndromes of, 286–291

Nephrogenic diabetes insipidus (NDI), pathophysiology of, 133
systemic disorders associated with, 129, 133–135

Nephrolithiasis, biochemical basis of, 1031–1033
childhood, **1001–1015**
clinical manifestations of, 1001–1002
cystinuria, 1007
Dent's disease, 1004–1006
diagnosis of, 1010
genetics of, 1003–1007
hematuria with, 1002–1003, 1006
hypercalciuria, 1002–1003, 1010–1012

infection-related, 1008–1009
miscellaneous causes, 1009
prevalence of, 1001
preventive medical therapy for, 1012–1013
primary hyperoxaluria, 1006–1007
Seyberth syndrome, 1003–1004
uric acid calculi, 1007–1008
diseases associated with, 1035
fixed-particle theory of, 1017–1018
free-particle theory of, 1017
from bowel disease, **979–999**
ammonium acid urate stones, 994–995
epidemiology of, 979–980
small bowel resection and, 985–994
total colectomy with ileostomy and, 980–984
hypercalciuric, **869–884**
genetics of, 877–880
absorptive, 877–879
other syndromes, 880
X-linked, 879–880
historical view, 869
hyperoxaluric, 927–943
hypocitraturic, 885–891
mechanisms of, 872–877
absorptive, 873–874, 1021
acquired, 875–876
genetic, 874–875
renal, 873, 877
resorptive, 873, 877
normal calcium homeostasis, 871–872
pathogenetic role of calcium, 869–871
hyperoxaluric calcium, **927–949**
diet and, 940–943
enteric, 939–940
small bowel resection and, 985–986
treatment of, 990–994
overview of, 927–928, 943
oxalate metabolism, 928–932
endogenous, 930–931
intestinal, 928–930
renal excretion, 931–932
primary, 932–939
clinical course of, 934–936
medical therapy for, 936–937
molecular pathophysiology of, 932–934
transplantation for, 936, 938–939
hyperuricosuric calcium, **915–925**
age and sex differences in, 917
calcium stones and, 920–921
clinical presentation, 916
definition of, 915
medical management of, 921–922
metabolic abnormalities, 916–917
physiochemistry, 917–920
calcium oxalate solubility and, 919–920
crystallography in, 918–919
inhibitor studies, 919
renal tubule blockage, 920
radiographic findings, 916
stone analysis, 915–916
surgical management of, 922–923
hypocitraturic, **885–893**
age and sex differences in, 888–889
causes of, 889–891
citrate metabolism, 885–888
acid-base parameters effect on, 888–891
in proximal tubule, 887–888
kidney reabsorption, 886
molecular mechanisms of transport, 887
other regulators of, 888
overall, 885–886
tubule transport, 886–887
epidemiology of, 888–889
management of, 891
pathogenesis of, 889–891
medical evaluation of, **1031–1050**
blood analysis, 1036–1037
calcium stones, 1038–1040
composition analysis, 1033–1034
computer iterative approximation programs for, 1038–1040
cystine stones, 1040–1041
in children, 1010
infectious stones, 1041
medical history, 1034–1035
normal limits of formation and urine variables of, 1041–1042
pathologic basis, 1031–1033
principles for, 1043–1045
radiographic examination, 1034
special investigations, 1041–1043
uric acid/urate stones, 915–916, 1040
urine analysis, 1037–1038
in children, 1010
medical treatment of, **1051–1064**
dietetic measures, 1052–1054
drugs for cystinuria, 1059

Nephrolithiasis, biochemical (*continued*)
drugs for hypercalciuria, 1054–1056
drugs for hyperoxaluria, 1056–1057
drugs for hyperuricosuria, 1057–1058
drugs for hypocitraturia, 1058–1059
drugs for struvite stones, 1060–1061
intake of liquids, 1051–1052
practical guideline for, 1061–1062
preventive, in children, 1012–1013
water intake, 1051–1052
nutritional aspects of, **1017–1030**
as risk factor, 1036, 1052–1054
calcium stones, 1019–1023
animal protein and sodium intake, 942–943, 1023–1024
calcium and oxalate intake, 1019–1023
citrate intake, 1024–1025
recommendations on, 943, 1025–1026
cystine stones, 1027
fluid intake, 1018–1019, 1051–1052
hyperoxaluria and, 940–943
theoretical overview of, 1017–1018, 1028
uric acid stones, 1026
physiochemistry of, clinical implications of, **855–867**
crystalization-based, 855, 858–864
solubility and supersaturation in, 855–860
hyperuricosuric calcium, 917–920
powderkeg and tinderbox theory of, 1027–1028
risk factors for, 1045
diet as, 1036, 1052–1054
low urine volume as, 1051–1052
pharmacologic treatment as, 1035–1036
surgical management of, 1073–1075. See also *Urolithiasis*.
large, 1074
small, 1073–1074
special considerations, 1075
uric acid, **895–914**
ammonium excretion physiology, 900–901
diagnosis of, 908–909
gout and, 903–904, 908
insulin resistance and, 904–908
nitrogen excretion evolution, 896–897
normal excretion of, 899–900
insulin and substrate role, 901
overview of, 895, 910
pathophysiology of, 901–908
genetic disturbances, 903–904
idiopathic, 904–908
schematic depiction of, 905
secondary causes, 901–903
physical chemistry of, 898–899
therapeutic intervention for, 909

Nephron, glomerular filtrate rate in, 858
tubular fluid supersaturation variations in, 861–862
urine crystallization inside, 860–861

Nephrotic syndrome, glucocorticoid therapy withdrawal analysis, 764

Nested case-control studies, of gene-environment interactions in type-2 diabetes mellitus, 557–558

Neuroendocrine response, to stress, 80

Neuroendocrine-immune regulatory loop, 1–3

Neuroimaging studies, of stress system, in major depression, 51–52

Neuropathy. See *Peripheral neuropathy*.

Neurosarcoidosis (NS), central diabetes insipidus associated with, 129–132

Neurovegetative symptoms, of major depression, 38–41

Neutrophils, in neonatal immune system, 283–284

Nicotinamide, in type-1 diabetes mellitus intervention trial, 482–483

967-979 deletion mutation, of *AIRE* gene, 326–327, 335

Nitrogen excretion, evolution of, 896–897
normal physiology of, 900–901

Noncalcareous calculi, 969–972. See also *Cystinuria; specific type, e.g.*, Struvite stones.

Nonendocrine tumor(s), proopiomelanocortin gene expression and, 191–197
classification of, 191, 197–199

Nonobese diabetic (NOD) mouse model, in immunomodulatory vaccination, 442–443

DNA vaccines and, 445–447
peptide/protein vaccines and, 443–445
in multiple sclerosis, 401
in self-tolerance restoration, 465–467
in type 1 diabetes mellitus
immunosuppressive therapy, 478–479, 483–484
of autoimmune polyglandular syndrome type IV, 435–437
of autoimmunity, 276, 278

Nonthyroidal illness syndrome, thyroid function in, **159–172**
anorexia nervosa and, 176–177
changes with, 160–163
physiology of, 159–160, 164–166
primary thyroid disease with, 166–168
tests of, 159–160
treatment of, 168
unusual patterns of, 163–164
with fasting, 159, 161–162
with HIV, 163
with psychiatric illness, 163
with surgery, 159, 161, 166

Nonvertebral fractures, and bone mineral density relationship to postmenopausal osteoporosis therapies, 665–666

Norepinephrine (NE). See also *Epinephrine*.
diet and weight loss effect on, 182–183
major depression and, 47–48, 51
sleep deprivation impact on, 21
stress response and, 81, 92

Northern blot analysis, of *AIRE* protein, 325

"No-test-no-treatment threshold," in evidence-based diagnosis, 579

Nuclear localization signal (NLS), of *AIRE* gene, 332–333

Nuclear receptor-binding motifs, of *AIRE* gene, 332–333

Nucleation induction time, in urine supersaturation, 858–859

NUDIST® database, for qualitative research, 591–592, 595

Nur77 mRNA, in POMC gene transcription, 192–194

Nutrition, diseases affecting, 173
in primary aldosteronism screening, 620, 624–626, 628
modification of, for cystinuria, 965–966
nephrolithiasis and, **1017–1030**
as risk factor, 1036, 1052–1054
of hypercalciuric, 870–871, 873
calcium stones, 1019–1023
animal protein and sodium intake, 942–943, 1023–1024
calcium and oxalate intake, 1019–1023
citrate intake, 1024–1025
in children, 1011
recommendations on, 943, 1025–1026
small bowel resection and, 990–992
cystine stones, 1027
fluid intake, 1018–1019, 1051–1052
hyperoxaluria and, 940–943
theoretical overview of, 1017–1018, 1028
uric acid stones, 917, 1026
thyroid function and. See *Malnutrition*.

Nutritional supplements, pathogenetic role in nephrolithiasis, dietary intake versus, 871–875
hyperoxaluria and, 940–943
in children, 1012–1013
recommendations on, 877–878, 943

O

Obesity, Cushing's syndrome and, 180–181, 200, 202
distinction of pseudo-Cushing's syndrome, 181–182
hormone secretion effects of, **173–189**
growth hormone, 177–178
weight loss with, 178
thyroid function, 174–175
treatment effects on, 175–176
hypothalamic-pituitary-adrenal axis
effects of, 179–181
diet effects on, 182–183
insulin resistance and, 180–181
prevalence of, 173
qualitative research on Bangladeshi beliefs on, 588, 594–595
sleep apnea and, 29–30

Observation, for qualitative research, 585, 589

Obstructive sleep apnea, body mass index in, 29–30
cytokines and, 28–31
physiology of, 17, 22, 25

Ocular disease(s), autoimmune polyendocrine syndrome type I and, 302, 304–305

OKT3, in self-tolerance restoration, 463–464, 466, 468

Oncogenes, in osteoclast bone resorption, 145

Online resources, for evidence-based medicine, 528–531

Open lithotomy, for hyperuricosuric calcium nephrolithiasis, 922–923
for urolithiasis, 1072–1073

OPG protein, hypercalcemia and, 146–149, 151

Opiate tolerance, adrenocorticotropic hormone and, 8

Opioids, central, stress response and, 65–67

Organic anion transporters (OAT), in uric acid excretion, 899–900

Orlistat, for obesity, growth hormone and, 178
thyroid function and, 176

Ornithine, in cystinuria pathology, 951–953
molecular basis of, 953–960

Orotic aciduria, childhood nephrolithiasis and, 1009

Orthophosphate, for hypercalciuria, 1055–1056
neutral, for primary hyperoxaluric, 937

Osmoreceptors, 121–122

Osteoblast, bone resorption of, in chronic renal failure, 112

Osteoclast, bone resorption of, in chronic renal failure, 112
in hypercalcemia, 143–147, 151
inhibition of, 152–154
precursors of, 145–147

Osteodystrophy, mixed uremic, 110–111, 114

Osteoporosis, evidence-based medicine example, 523–524, 660–663
postmenopausal. See *Postmenopausal osteoporosis*.

Ovarian failure. See *Premature ovarian failure (POF)*.

Ovarian follicle(s), hormonal regulation of, 65
in major depression, 68–70

Ovarian hormone(s), major depression effects of, 72–73
premenstrual syndrome and, 71–72

OVID, as evidence-based medicine resource, 529–530
problem-based examples of, 532–533

Ovulation, chronic renal failure and, 116–117
hypothalmic-pituitary-gonadal axis regulation of, 65–67
major depression and, 68–70

Oxalate intake, as nephrolithiasis risk factor, 1036, 1053–1054
background on, 1019–1020
evaluation of, 1038–1040
in children, 1012–1013
low versus high calcium intake and, 1020–1023
pathogenetic role, 869–871
recommendations on, 943, 1025–1026
small bowel disease and, 983–985
recommendations for, 990–993
nutritional sources of, 941, 1022–1023

Oxalate metabolism, calcium stones and. See *Calcium oxalate (CaOx) stones*.
endogenous, 930–931
in hyperoxaluric calcium nephrolithiasis, 928–932
in hyperuricosuric calcium nephrolithiasis, 917–920
in nephrolithiasis, childhood, 1006–1007
solubility and, 856–857
in uric acid nephrolithiasis, 905–908
intestinal, 928–930
alterations with bowel resection, 987–989
renal excretion, 931–932
"salting out" phenomenon of, 919–920

Oxalobacter formigenes, in oxalate metabolism, 929–930, 939
small bowel resection impact on, 989

Oxygen consumption (VO_2), epinephrine toxicity and, in cardiac arrest, 89, 91
growth hormone effects of, 178

Oxygen therapy, systemic hyperbaric, for diabetic foot ulcers, 609

P

Pain perception, fibromyalgia and, 7–8

Pamidronate (Aredia), for hypercalcemia, 152, 154

Pan-American Health Organization (PAHO), in iodized salt for iodine deficiency review, 682, 684

Pancreatic β-cells, in animal models of autoimmunity, 435–438
in neonatal autoimmune diabetes, 287–289
in type 1 diabetes mellitus, immunomodulatory vaccination and, 442–444
immunosuppressive therapy for, 477–478, 480–482
monoclonal antibodies relevance to, 465–467, 469
in type-2 diabetes mellitus, 554, 558

Pancreatic islet cell tumors, ectopic proopiomelanocortin syndrome and, 198, 203–204

Paracellin-1 protein, hypercalciuric nephrolithiasis association with, 880

Parasomnias, 17

Parathyroid gland(s), ablation therapy for, for chronic renal failure, 113–114

Parathyroid hormone (PTH), chronic renal failure and, diagnosis of, 111–114
extra skeletal effects of, 110–111
management of, 111–114
pathophysiology of, 108–109
skeletal effects of, 109–110
deficiency of. See *Hypoparathyroidism*.
hypercalcemia and, 145, 149–150, 154
in calcium homeostasis, 871–872
in hypercalciuric nephrolithiasis, 877, 880
in children, 1010
in postmenopausal osteoporosis trials, 805

Parathyroid hormone-related protein (PTHrP), hypercalcemia and, 143, 145–148
malignancies and, 150

Parathyroidectomy, for chronic renal failure, 114

Paraventricular nucleus (PVN), of hypothalamus, melancholic depression and, 49–51
water homeostasis and, 122, 127, 130

Parietal-cell antibodies (PCA), gastric, in autoimmune polyendocrine syndrome type II, 380–382, 384
diagnostic approach to, 342, 346
type 1A diabetes mellitus-associated autoimmunity and, 402–403

Patient education, for diabetic foot ulceration prevention, systematic review of, **633–658**
as component of general education versus usual care, 647, 651
background on, 633–635
complex intervention for patients and doctors versus usual care, 647, 652
data analysis, 636–639
data extraction form, 636, 639
discussion on, 654–656
included study characteristics, 635–636, 640–645
intensive tailored intervention versus usual care, 647, 653–654
intensive versus brief intervention, 645, 647–650
interventions summarized, 639, 645
methods for, 635–639
quality assessment of, 645–646, 656
results analysis, 639, 645, 647–654
search strategies, 702–703
study limitations, 655–656

Pattern recognition receptors (PRR), in immunology, 261

Peer review, in evidence-based medicine, 824–825

Penicillamine, for cystinuria, 1059

Peptide vaccines, autoimmune disease and, 443–445, 448–449

Peptides, antigen processing and, 267–270
in autoimmunity, 411, 417

Percutaneous nephrolithotomy (PNL), evolution of, 1068
for cystinuria, 968, 971–972
for nephrolithiasis, 1073–1075
hyperuricosuric calcium, 922–923
lithotripsy techniques, electrohydraulic, 1070

Percutaneous (*continued*)
laser, 1070–1071
pneumatic, 1069–1070
ultrasonic, 1068–1069

Peripheral antigen-expressing cells, in autoimmunity, 412–413, 420–425

Peripheral neuropathy, diabetic foot ulcers with, biosynthetic dermis for, 607–609
off-loading of, 607–608
risk factors for, 604–605
systemic antibiotic therapy for, 609
systemic hyperbaric oxygen for, 609
topical growth factors for, 607–609
treatment of, 607
evidence-based diagnosis of, 569, 574

Pernicious anemia, autoimmune polyendocrine syndrome type I and, 300, 309
autoimmune polyendocrine syndrome type II and, 380–381
diagnostic approach to, 342–344, 346
treatment of, 349–350
type 1A diabetes mellitus-associated autoimmunity and, 402–403

Peroxisome proliferator-activated receptor γ (PPARγ) gene, Pro12A1a variant of, in type-2 diabetes mellitus, 555–556, 559–560, 562

PGE_2, as nephrolithiasis factor, 875–876

pH, urinary profile with nephrolithiasis, 1038–1041, 1043
effect on citrate metabolism, 886, 888
nitrogen excretion and, 896–897
solubility and, 857
struvite calculi and, 969–970
uric acid, 898–899, 901–903, 905–908
ammonium stones and, 994–995
bowel disease and, 981–982

Phagocytosis, in immunology, 261, 269
neonatal, 283–284

PHD domains, of *AIRE* gene, 330–332, 334–335

Phosphate, analysis for nephrolithiasis, calcium stones, 1038–1040
serum, 1010, 1037
for childhood nephrolithiasis, 1012–1013

Phosphorus, for hypercalcemia, 155

Phosphorus homeostasis, chronic renal failure and, diagnosis of, 111–114
extra skeletal effects of, 110–111
management of, 111–114
pathophysiology of, 108–109
skeletal effects of, 109–110

Physician(s), evidence-based medicine implementation role, 805–807

Physiochemistry, of urolithiasis, **855–867**
crystallization as basis of, 855, 858–860
crystallization inside the nephron, 860–861
crystalluria versus stone formation, 862–864
hyperuricosuric calcium, 917–920
solubility and, 855–857
supersaturation and, 855–857
supersaturation resulting in crystallization, 858–860
supersaturation variations in tubular fluid, 861–862
urine supersaturation process, 858

Pile sorting exercises, for qualitative research, 590

Pituitary gland(s), central diabetes insipidus and, 130–131
corticotrope cells of, in POMC modification and processing, 194–195
in POMC transcription regulation, 192, 194
obesity effects on, 179
ectopic anterior, corticotropin production by, 199
plasma osmolality regulation by, 121–123
stress response and, 80–81, 83

Plasma aldosterone concentration. See *Aldosterone-to-renin ratio (ARR)*.

Plasma epinephrine, in acute severe stress, cardiac arrest and, 89–97
concentrations of, 83–84
human addictions mediation of, 96–97
kinetics of, 85–86

Plasma osmolality, arginine vasopressin regulation of, 121–123
systemic disorders impact on, 123–135

Plasma renin activity. See *Aldosterone-to-renin ratio (ARR)*.

Platelets, in diabetic retinopathy, 780–781
treatment of. See *Aspirin therapy*.

Pneumatic lithotripsy, for percutaneous nephrostolithotomy, 1069–1070

Pneumococcal vaccine, autoimmune polyglandular syndrome type I indications for, 311

Policy mandates, qualitative research on, 586, 595–596, 599

Polyallylamine hydrochloride (sevelamer), for chronic renal failure, 112

Polyendocrinopathy, autoimmune. See *Autoimmune polyglandular syndromes (APS)*.
neonatal, **283–293**
adaptive immune response and, 285–286
autoimmune syndromes of, 286–291
innate immune system and, 283–285

Polymorphonuclear cells (PMN), in neonatal immune system, 284

POMC gene expression. See *Proopiomelanocortin (POMC)*.

Population genetics, of autoimmune regulator, **321–338**, 392

Population screening. See *Genetic screening*.

Position/positioning, in primary aldosteronism screening, 621, 624–626, 628

Positive predictive value (PPV), in evidence-based diagnosis, 573–574

Postmenopausal osteoporosis, bone density and fractures relationship to therapies for, metaanlyses summary of, **659–679**
absolute differences in event rates, 666–667
background on, 659–660
bone density changes and fractures relationship, 669–674
bone density results, 667–669
comparison of treatment effects between, 663
management implications, 674–676
methodologic quality of studies, 660–663
nonvertebral fractures results, 665–666
vertebral fractures results, 663–665

Postpartum depressive episode, 64

Posttest probabilities, in evidence-based diagnosis, 574–576, 579
calculation of, 580–581

Potassium, nephrolithiasis and, hypocitraturic, 890–891
risk factor, 1037, 1053–1054

Potassium citrate, for childhood nephrolithiasis, 1012
for hyperuricosuric calcium nephrolithiasis, 921
for hypocitraturia, 891
for primary hyperoxaluric, 937
for uric acid nephrolithiasis, 909

Powderkeg and tinderbox theory, of nephrolithiasis, 1027–1028

Practice guidelines. See *Clinical practice guidelines*.

Predictive values, in evidence-based diagnosis, 573–574
clinical examples of, 627

Prednisolone, dosage reduction analysis, 753, 757

Prednisone, for autoimmune polyglandular syndrome type I, 311

Prefrontal cortex, functional components of, 44–45
major depression and, 41, 51–52
stress response and, 44–46
neuroimaging of, 51–52

Pregnancy, chronic renal failure and, 117

Pregnancy education, qualitative research on, 597–598

Premature ovarian failure (POF), autoimmune polyendocrine syndrome type I and, treatment of, 311–312
autoimmune polyendocrine syndrome type II and, 341, 373, 376–378
treatment of, 349

Premenstrual syndrome (PMS), major depression association with, 64
ovarian steroids' effects on, 72–73
ovarian hormones in, 71–72

Pretest probabilities, in evidence-based diagnosis, 574–576, 579
calculation of, 580–581

Primary aldosteronism, aldosterone-to-renin ratio test for, **619–632**

Primary aldosteronism (*continued*)
current status of, 619–620
systematic review of, 619–629
data analysis, 621
data extraction form, 620–621
discussion on, 623, 627–629
included trials characteristics, 622–626
materials and methods for, 619–621
performance results, 623, 627
quality assessment of, 621–622
results of, 621–627
search strategies, 620
trials selection, 621–622

Primary gout, uric acid nephrolithiasis with, 903

Primary hyperoxaluria (PH), 932–939
clinical course of, 934–936
in childhood nephrolithiasis, 1006–1007
medical therapy for, 936–937
molecular pathophysiology of, 932–934
prevalence of types, 934–935
transplantation for, 936, 938–939

Pro12A1a variant, of peroxisome proliferator-activated receptor γ gene, in type-2 diabetes mellitus, 555–556, 559–560, 562

Probabilities, pretest versus posttest, in evidence-based diagnosis, 574–576, 579
calculation of, 580–581

Problem-solving strategy, evidence-based medicine as, 521–522

Process evaluation, in qualitative research, 586, 599–600

Progesterone, for autoimmune polyglandular syndrome type II, 349
for premenstrual syndrome, 72
hypothalamic-pituitary-gonadal axis regulation of, 65
major depression and, 69–70

Proline-rich region (PRR), of *AIRE* gene, 332

Proopiomelanocortin (POMC), ectopic syndrome of, **191–234**
ectopic tumor producing, classification of, 191, 197–199
POMC gene expression and processing with, 192–194
hypersecretion effects of, adrenal gland, 196–197
extra-adrenal, 197
hypothalamic-pituitary-adrenal axis and, 3
modification and processing of, 194–195
ectopic tumor production in, 195
neuroendocrine-immune regulatory loop and, 3, 80
reproductive axis and, 67
transcription regulation of, 192
ectopic tumor production in, 192–194, 216

Prostaglandins, hypercalcemia and, 145–147

Protease inhibitors, noncalcareous calculi from, 972

Protein(s), membrane-associated, in hypercalcemia, 143, 146–151, 156

Protein intake. See *Animal proteins*.

Protein vaccines, autoimmune disease and, 443–445, 448–449

Proteinuria, as evidence-based diagnosis for diabetes, 567–570, 575

Proteolipid protein (PLP), myelin, autoimmune response to, 412
self-molecule expression with, 419–420
in multiple sclerosis, 400–401

Protocol, for clinical trials, 617

Proximal tubule, citrate handling in, 887–888
uric acid excretion in, 899–900

Pro-γ-melanotropin, adrenocortical growth and, 196–197

Psychiatric illness, thyroid function changes with, 163

Psychological disorder(s), autoimmune polyendocrine syndrome type I and, 305, 315–316
major depression as, 38–40, 64

PubMed. See *MEDLINE*.

Pulmonary disorder(s), syndrome of inappropriate antidiuretic hormone secretion associated with, 124, 127–128

Pulmonary sarcoidosis, glucocorticoid therapy withdrawal analysis, 764

Purine, uric acid nephrolithiasis and, 902–903, 917, 920–921

Pyelolithotomy, coagulum, for urolithiasis, 1072–1073

Pyridoxine, for childhood nephrolithiasis, 1013
for hyperoxaluria, 1057
for primary hyperoxaluric, 937

Q

Qualitative research, as hypothesis-generating, 585–587
integrating into evidence-based medicine, **583–601**
biomedical fit, 585–587
designs for, 583–585
evaluative on practice, 599–600
explanatory on complex interventions, 596–599
exploratory on health beliefs, 587–596
background on, 587–588
methods for, 588–594
results analysis, 594–596
question characteristics for, 583

Quality improvement, in evidence-based medicine, 824–825

Quality of life, as evidence-based medicine factor, 587, 615
chronic renal failure and, 107–108, 117

Quantitative research, as hypothesis-testing, 585–587
designs for, 584
on traits with gene-environment interactions in type-2 diabetes mellitus, 558–559, 562
qualitative research step in question characteristics for, 583

Question definition/refinement, in evidence-based practice development, 803

R

R257X mutation, of *AIRE* gene, 326, 334

Radiobinding assays, for autoimmune polyendocrine syndrome type II, 372–373, 381

Radiography, for ectopic Cushing's syndrome, 214–215
for nephrolithiasis analysis, 916, 1034
crystallographic, 909, 918–919, 1033–1034

Raloxifene, in postmenopausal osteoporosis trials, 661

Randomization, concealment of, in osteoporosis trials, 660, 662–663

RANK protein, hypercalcemia and, 146–149

RANKL protein, hypercalcemia and, 146–149, 151, 156

Rapid eye movement (REM) sleep, adrenal insufficiency and, 25–26
age impact on, 16
stress impact on, 17–19

Rat models, of autoimmune polyglandular syndrome type II, 434–435
of autoimmunity, 277
of monoclonal antibodies, in self-tolerance restoration, 464–465, 468

rBAT glycoprotein, in cystinuria pathology, 952, 954–956
non-Type I, 958–960
Type I, 956–958

Receiver operating characteristic (ROC) curve, in evidence-based diagnosis, 571–573

Recombinant human erythropoietin, for chronic renal failure, 114–116

Recommendation formation, in evidence-based practice development, 804–805

Reference standard, in evidence-based diagnosis, 568–569
clinical examples of, 627–628

Relative risk, of diabetes mellitus complications, 546
of postmenopausal osteoporosis, 663–666, 671–673

Renal calculi. See *Nephrolithiasis*.

Renal collecting duct cells, water homeostasis and, 122–123, 133–135

Renal disease, autoimmune polyendocrine syndrome type I and, 303, 305
calciferol replacement therapy and, 313–314
end-stage. See *Chronic renal failure*.
hypercalcemia and, 141, 143–144, 151
treatment of, 152–153

Renal excretion, of albumin, as evidence-based diagnosis for diabetes, 568, 570–571
of ammonium. See *Ammonium excretion*.
of citrate, 885–888
acid-base parameters effect on, 888
pathogenic, 889–891
age and sex differences in, 888–889

Renal excretion (*continued*)
in proximal tubule, 887–888
molecular mechanisms of transport, 887
other regulators of, 888
overall, 885–886
reabsorption, 886
tubule transport, 886–887
of 17-hydroxysteroids, 19, 21
of iodine, 683, 691–693
of nitrogen, 896–897, 900–901
of oxalate, 931–932
of uric acid excretion, 899–901
of water. See *Free water excretion.*

Renal hypercalciuria, nephrolithiasis with, 873, 877

Renal tubular acidosis (RTA), childhood nephrolithiasis and, 1003, 1011
hypercalciuric nephrolithiasis with, 880
hypocitraturic nephrolithiasis with, 889–891

Renal tubules, citrate transport by, 886–887
molecular mechanisms of, 887
uric acid excretion by, 899–900
blockage of, 920
in children, 1008

Renin activity, plasma. See *Aldosterone-to-renin ratio (ARR).*

Reproducibility, of evidence-based diagnosis, 576–580

Reproductive hormone(s). See also *specific hormone, e.g., Testosterone.*
hypothalmic-pituitary-gonadal axis regulation of, 65–67
major depression and, 68–70

Reset osmostat, syndrome of inappropriate antidiuretic hormone secretion with, 124, 126

Resorptive hypercalciuria, nephrolithiasis with, 873, 877

Resource utilization, clinical practice guidelines impact on, 808–810

Retinopathy. See *Diabetic retinopathy.*

Reverse transcription-polymerase chain reaction (RT-PCR), for self-molecules, in autoimmunity, 412–413, 421, 424–425

Rheumatic disease(s), hypothalamic-pituitary-adrenal axis and, **1–13**
animal models of, 3–5, 8
arthritis and, 5–7
fibromyalgia and, 8–9
stress and pain impact on, 7–9
physiology of, 1–3
Sjögren's syndrome and, 7
systemic lupus erythematous and, 4–5, 7

Rheumatoid arthritis (RA), hypothalamic-pituitary-adrenal axis in, 5–7

Risedronate, in postmenopausal osteoporosis trials, 661

Risk and risk factors, epidemiologic analyses of, **537–551**
categorical variables of, 540–541
characteristics of, 540–541
continuous variables of, 540–541
date collection over time versus at point in time, 542–543
etiology and pathogenesis implications of, 546–547
measurements, exposures, and factors of, 540–541
outcome constructions, 541–542
population characterization, 539
progressive variables of, 541
research establishment of, 539
scope of, 537–538, 548–550
statistical expression of, 545–546
therapy implications of, 548–549
of cardiovascular events in diabetes with albuminuria, HOPE study
baseline measurements and factors, 541
HOPE study data analysis, 543–1267
HOPE study design, 538–539
HOPE study population, 539–540
of postmenopausal osteoporotic fractures, 662–667, 671–673, 675
term refinement, 547

Risk indicators, of diabetes mellitus complications, 538, 547

Risk markers, of diabetes mellitus complications, 538, 547

Risk/benefit analysis, in evidence-based medicine, 824

RU486, for premenstrual syndrome, 72

Rubella syndrome, congenital, type 1A diabetes mellitus-associated autoimmunity and, 401–402

S

Salt (NaCl), nephrolithiasis and, as risk factor, 1053
background on, 1023–1024

hypocitraturic, 890
intake, animal protein, and recurrences, 1024
recommendations on, 1025–1026

Salt iodination. See *Iodized salt*.

Salt loading, in primary aldosteronism screening, 623–628

"Salting out," in calcium oxalate stone formation, 919–920

SAND domain, of *AIRE* gene, 329–331, 334–335

Schmidt's syndrome. See *Autoimmune polyglandular syndrome type II (APS II)*.

Science Citation Index (SCI-EXPANDED), in glucocorticoid withdrawal schemes review, 754, 757, 772

Scintigraphy, somatostatin receptor, for ectopic Cushing's syndrome, 215–216

Screening. See *Genetic screening*.

Search strategy(ies), for systematic reviews and metaanlyses. See *specific topic*.

Seasonal affective disorder, 54–55

Selectins, in neonatal immune system, 284

Selective IgA deficiency, type 1A diabetes mellitus-associated autoimmunity and, 399–400

Self-antigens, 266, 276, 458

Self-molecule expression, in autoimmunity, 411–412
cells involved in, 273, 279, 420–425
conclusions about, 426
differential, 413, 416–420
in thymus and lymphoid organs, 412–415

Self-tolerance. See also *Autoimmunity*.
in autoimmunity, 274–276, 412, 417
monoclonal antibodies restoration of, **457–475**
CD3 antibodies and, 458–460, 466–469
diabetes relevance, 465–466
diabetes reversal with, 466–467
introduction to, 457–458, 469–470
mode of action, 461–464
receptor specificities, 458–461
tolerogenic properties of, 464–465

Semmes-Weinstein monofilament, for diabetic foot assessment, 634–635

Sensitivity, in evidence-based diagnosis, 570–571

Serotonin uptake blockers, major depression and, 47–48, 51

Sertaline, for major depression, ovarian steroids' influence on, 73

Severe combined immunodeficiency (SCID), 264–265

Sexual dysfunction, chronic renal failure and, 116–117

Seyberth syndrome, in childhood nephrolithiasis, 1003–1004

Shift work, sleep cycles and, 15

Shock wave lithotripsy (SWL), extracorporeal, for cystinuria, 967–968, 971
for nephrolithiasis, 1073–1075
hyperuricosuric calcium, 922–923
for urolithiasis, coupling of shock wave, 1067
instrumentation for, 1066–1067
third generation, 1067–1068
shock wave focusing, 1066–1067
shock wave generation, 1066
stone localization, 1067
techique evolution, 1065–1066

Sick euthyroid syndrome. See *Nonthyroidal illness syndrome*.

Side-chain cleavage enzyme autoantibodies (P450sccAb), immunomodulatory vaccination and, 442
in autoimmune polyendocrine syndrome type II, 369, 376–378, 383
diagnostic approach to, 343

Signaling pathway, of co-stimulation response, 265

Sildenafil, chronic renal failure and, 117

Silicate stones, 972

Sjögren's syndrome, animal models of, 436
hypothalamic-pituitary-adrenal axis in, 7

Skin disease(s), autoimmune polyendocrine syndrome type I and, 303
diagnostic approach to, 306
treatment of, 311–312
autoimmune polyendocrine syndrome type II and, 371, 373, 382
diagnostic approach to, 341, 346

SLC3A1 gene, in cystinuria pathology, 952, 956
Type I, 956–957, 959

SLC7A9 gene, in cystinuria pathology, 956
non-Type I, 958–960

Sleep and sleep cycle, age impact on, 15–17, 20, 28
cytokines and, 26–31
age impact on, 28
disordered/disturbed physiology of, 28–31
normal physiology of, 27–28
diurnal patterns of, 15–16
cortisol production and, 8–9
hypothalamic-pituitary-adrenal axis, **15–36**
age impact on, 20
cytokines impact on, 26–31
disordered/disturbed physiology of, 21–26
normal physiology of, 17–21
sleep deprivation impact on, 20–21
stress response and, 15, 17–22

Sleep apnea, Cushing's syndrome and, 25
obstructive, body mass index in, 29–30
cytokines and, 28–31
physiology of, 17, 22, 25

Sleep deprivation, hypothalamic-pituitary-adrenal axis and, 20–21

Sleep disorder(s), 17. See also *specific disorder, e.g., Daytime sleepiness.*
antidepressants for, 22
cytokines and, 28–31
hypothalamic-pituitary-adrenal axis and, 21–26

Slow-wave sleep (SWS), age impact on, 17, 20
cytokines impact on, 28
stress impact on, 17, 20

Small bowel resection, nephrolithiasis associated with, 985–994
calcium stones, 985–994
diet recommendations for, 990–992
etiology, 985–986
incidence, 986–987
oxalate transport and, degrading bacteria impact on, 989
increased luminal ionic concentration, 988–989
mucosal permeability alterations, 987–988
normal, 987
supersaturation with, 989–990
treatment of, 990–994
uric acid stones, 994

Small cell lung carcinoma (SCLC), ectopic proopiomelanocortin syndrome and, 198, 203–204
POMC gene transcription and, 193–194
syndrome of inappropriate antidiuretic hormone secretion associated with, 125

SMART (Simple Modular Architectural Research Tool), for *AIRE* gene analysis, 330–331

Societal impact, of clinical practice guidelines, 810

Sodium. See *Salt (NaCl).*

Sodium balance, nephrogenic diabetes insipidus and, 133–135
water homeostasis and, 123, 126

Sodium cellulose phosphate, for hypercalciuria, 1055

Sodium-iodide symporter autoantibodies (NISAb), in autoimmune polyendocrine syndrome type II, 379–380

Solubility, in nephrolithiasis physiochemistry, 855–857

Somatostatin receptor scintigraphy, for ectopic Cushing's syndrome, 215–216

Specificity, in evidence-based diagnosis, 570–571

Spectroscopy, infrared, for nephrolithiasis analysis, 919, 1033–1034

Spermatogenesis, chronic renal failure and, 116

Spleen, atrophy of, with autoimmune polyglandular syndrome type I, 297
diagnostic approach to, 309
treatment of, 311

Spot urine sample, for nephrolithiasis, 1037–1038

Staghorn calculi, in cystinuria, 960–963

Stakeholders, in evidence-based medicine, 823–824

Starvation. See *Malnutrition.*

Statistical power, in gene-environment interactions in type-2 diabetes mellitus studies, 559, 562

Steatorrhea, nephrolithiasis from, 986
  diet recommendations for, 990–992
  oxalate metabolism and, 987–989
  surgery associated with. See *Small bowel resection.*
  treatment of, 990–994

Steroid withdrawal syndrome, 752

Steroidogenesis, corticotropin in, 196

Steroid-producing cell autoantibodies (SCA), in autoimmune polyendocrine syndrome type II, 376–378, 383
  diagnostic approach to, 344, 346

Storytelling, for qualitative research, 588, 590–591
  results analysis, 594–596
  study methods, 588–594

Stress and stress response, autoimmune polyendocrine syndrome type I and, 305, 310, 316
  categorization of, 80–81
  consistency in, 40–41
  epinephrine role in, **79–106**
    actions of, 84–85
      in cardiac arrest, 85
    adrenosympathetic system in, 83
    afferent pathways of, 81–82
    categorizations in, 80–81
    efferent pathways of, 82–83
    hormone responses in, 80, 83
    neuroendocrinology of, 80
    plasma concentrations in acute severe stress, 83–84
    plasma kinetics of, 85–86
    toxicity of, 86
      cardiovascular effects of, 86–87
      in cardiac arrest, 89–97
      metabolic effects of, 87–88
      with preexistent heart disease, 88–89
  fibromyalgia and, 7–9
  major depression and, 40–46, 64
    amygdala role in, 44
    core stress system in, 41, 47–51
    CRH system in, 41–44, 48–51
    LC-NE system in, 41, 45, 47–48
    neurobiology of, 40–46
    neuroimaging studies of, 51–52
    pathophysiology of, 47–52
    phenomenology of, 40–41
    prefrontal cortex role in, 41, 44–46
  neuroendocrine-immune regulatory loop in, 1–3
    animal models of, 3–5, 8
  reproductive axis and, 65–67
  simplicity in, 40
  sleep and, 17–22, 25
  speed in, 40

Stress-induced analgesia, 8

Stress-related syndromes, 8

Structured vignette, for qualitative research, 593–596

Struvite stones, in nephrolithiasis, 969–972
  composition analysis of, 1033–1034
  dietetic factors of, 1052–1054
  drug therapy for, 1060–1061

Study(ies), as evidence-based endocrinology resource, 530–531

Study design(s), for gene-environment interactions in type-2 diabetes mellitus, as binary state versus continuum, 557–558, 562
  historical epidemiological, 553–557
  size requirements for detection, 559, 562

Suby's solution, for struvite calculi, 971

Supersaturation, of urine. See *Urine supersaturations.*

Supraoptic nucleus (SON), of hypothalamus, water homeostasis and, 122, 127, 130

Surgery, thyroid function changes with, 159, 161, 166

Surrogate marker, of diabetes mellitus complications, 548–549

Surrogate outcomes, of diabetes mellitus complications, 542

Survival, with autoimmune polyglandular syndrome type I, 316

Sweating, excessive, uric acid nephrolithiasis with, 902

Sympathetic nervous system, insulin resistance and, 181
  sleep apnea and, 22, 25
  stress response and, 41–42, 44, 83
    epinephrine pathways in, 81–83

Sympathin, 79

Syndrome of inappropriate antidiuretic hormone secretion (SIADH), central nervous system disorders and, 124, 126–127
pathophysiology of, 123
pulmonary disorders and, 124, 127–128
reset osmostat and, 124, 126
systemic disorders associated with, 123–124
tumors and, 123–125

Synopses, as evidence-based endocrinology resource, 529, 603, 609

Syntheses, as evidence-based endocrinology resource, 528–530. See also *Systematic literature reviews*.

Systematic literature reviews, as evidence-based medicine resource, 528–530, 795, 801–802
by Cochrane Metabolism and Endocrine Disorders Review Group, **613–617**
on aspirin in diabetic retinopathy, **779–792**
on diabetic foot care, **603–611**
on glucocorticoid withdrawal schemes, **751–777**
on human versus animal insulin for diabetes mellitus, **723–749**
on iodized salt for iodine deficiency, **681–697**
on patient education on diabetic foot ulceration, **633–658**
on thyroid disease, **793–815**
on thyroid nodule pharmacotherapy, **699–721**

Systemic disease(s), thyroid function changes with, **159–172**
water homeostasis and, excess arginine vasopressin in, 123–128
insufficient arginine vasopressin in, 128–135

Systemic lupus erythematosus (SLE), hypothalamic-pituitary-adrenal axis in, 7
animal models of, 4–5

Systems information, as evidence-based endocrinology resource, 528–529

T

Tamm Horsfall protein (THP), as nephrolithiasis factor, 859, 864

TAP gene, in immunology, 268–269

Target cell depletion, in self-tolerance restoration, 462–463

T-cell receptor (TCR), antigen recognition by, 262, 264–265
in self-tolerance restoration, 458–464
HLA system and, 273–274
in autoimmunity, 411, 416–417, 419
monoclonal antibodies restoration of, 458–461
in immunomodulatory vaccination, 445, 448, 451

T-cells. See *T-lymphocytes*.

"Test threshold," in evidence-based diagnosis, 579

Testosterone, major depression and, 69–70

Textual analysis, for qualitative research, 591–592

Th1 cells, as helper T-cell subset, 265, 277
in immunomodulatory vaccination, 443, 445–446, 448–450

Th2 cells, as helper T-cell subset, 265, 277
in immunomodulatory vaccination, 443–446, 448–449

T-helper (Th) subtypes, corticosteroid regulation of, 3
in acquired immunology, 265, 277
in self-tolerance restoration, 458–460, 462–465
diabetes and, 465–469

Thermic effect, of glucose, 182–183

Thiazide diuretics, for hypercalciuria, 1054–1055
for hyperuricosuric calcium nephrolithiasis, 921
hypocitraturia and, 890–891

Thick ascending limb (TAL), of loop of Henle, in nephrogenic diabetes insipidus, 133–135

Thiocarbamides, for autoimmune polyglandular syndrome type II, 349

Thirst, central diabetes insipidus and, 131
osmotic threshold for, 122

Thymic carcinoids, ectopic proopiomelanocortin syndrome and, 198, 204–205

Thymocyte maturation, corticosteroid regulation of, 3

Thymus gland, in autoimmunity, 411–412
animal models of, 436

insulin gene expression and, 276–277
self-molecule expression with, 412–415
cells involved in, 420–425
in self-tolerance restoration, 464–465
lymphocyte development and, 273

Thyroglobulin autoantibodies (TGAb), in autoimmune polyendocrine syndrome type II, 369, 379–382
animal models of, 433
diagnostic approach to, 342–345
type 1A diabetes mellitus-associated autoimmunity and, 396

Thyroid cancer, epidemiology of, 699–700
pharmacotherapy for. See *Thyroxine suppressive therapy*.

Thyroid disease, clinical practice guidelines for, evidence-based, **793–815**
clinical algorithm for, 794, 800
clinical pathways for, 794, 800
collecting information for, 794–795, 801–802
computers for implementation, 807
implementation of, 805–807
individual impact of, 810–811
limitations of, 807–810
review of available, 794, 796–799
societal impact of, 810–811
steps in development of, 802–805
tools for advocating, 795, 800
nodular. See *Thyroid nodules*.

Thyroid hormone(s), anorexia nervosa effect on, 176–177
hypothyroidism versus, 177
nonthyroidal illness syndrome and, action on heart, 166
function test changes with, 159–160, 164–166
kinetic changes in, 162
metabolism of, 160
physiology of, 159–160, 164–166
primary thyroid disease with, 166–168
receptor genes in, 165–166
regulation of, 159–160
serum concentration changes with, 160–163
transport of, 160
treatment of, 168
unusual patterns of, 163–164
obesity effect on, 174–175
treatment effects on, 175–176

Thyroid hormone receptor, nonthyroidal illness syndrome and, 165–166

Thyroid nodules, evidence-based medicine example, 522, 576
pharmacotherapy review and meta-analysis, **699–721**
adverse effects of, 714
clinical problem of, 699–701
data analysis, 755–756
data extraction form, 755
discussion on, 716–717
excluded trials, 704–705
included trials characteristics, 704, 706–708
inclusion criteria, 701–702
interventions and compliance assessment, 704–705, 709
methods for, 701–704
nodule growth effects, 709–713
nodule size changes, 709, 714–715
outcome measures, 702, 705
quality assessment of, 703
research evidence review, 701
results analysis, 704–716
search strategies, 702–703
trials selection, 702–703

Thyroid-stimulating hormone (TSH), anorexia nervosa and, 176–177, 185
in autoimmune polyglandular syndrome type II, 344, 346
nonthyroidal illness syndrome and, hypothalamic-pituitary-thyroid axis and, 162–163
physiology and tests of, 159–160, 165
primary thyroid disease versus, 166–168
serum concentrations of, 162
obesity and, 174–176, 185
suppression of. See *Thyroxine suppressive therapy*.

Thyroperoxidase autoantibodies (TPOAb), in autoimmune polyendocrine syndrome type II, 369, 379–382
diagnostic approach to, 342–345
type 1A diabetes mellitus-associated autoimmunity and, 396

Thyrotoxicosis, in neonates, 289

Thyrotropin. See *Thyroid-stimulating hormone (TSH)*.

Thyrotropin-releasing hormone (TRH),
anorexia nervosa and, 176
obesity and, 174–175

Thyroxine (T4), anorexia nervosa and, 176–177
nonthyroidal illness syndrome and, as treatment, 168
hypothalamic-pituitary-thyroid axis and, 162–163
physiology and tests of, 159–160, 164–165
primary thyroid disease versus, 166–167
reduced concentration of, 161–162
obesity and, 174–175, 185

Thyroxine suppressive therapy, evidence-based clinical practice guidelines for. See *Thyroid disease*.
review and meta-analysis of, 699–721
clinical indications for, 699–701
discussion on, 716–717
methods for, 701–704
research evidence review, 701
results analysis, 704–716

Thyroxine-binding globulin (TBG),
anorexia nervosa and, 176
nonthyroidal illness syndrome and, 160, 164–165
obesity and, 174, 176

Time zones, sleep cycles and, 15

Tiopronin, for cystinuria, 1059

Tissue transglutaminase autoantibodies (TTGAb), in autoimmune polyendocrine syndrome type II, 347, 371, 381, 383
in celiac disease, 393–394

Title proposal, for clinical trials, 617

T-lymphocyte antigen-4. See *Cytotoxic T-lymphocyte antigen-4 (CTLA-4)*.

T-lymphocytes, as interleukin source, 265–267
HLA system and development of, 273–274
in autoimmune polyendocrine syndrome type II, 370, 434
in autoimmunity, deletion of, 276, 420–425
monoclonal antibodies and, 461–465
therapeutic, 278–279
regulatory role of, 274–275, 277–278
in immunology, 457
acquired antigen recognition and, 264–265
helper subsets of. See *T-helper (Th) subtypes*.
neonatal, 285–287
in immunomodulatory vaccination, 443–445, 447–452
in type 1 diabetes mellitus immunosuppressive therapy, 478–480, 486–487

Tolerance, in immunology, 274–276. See also *Self-tolerance*.

Topical growth factors, for noninfected diabetic foot ulcers, 607–609

Total body bone mineral density, and fracture relationship to postmenopausal osteoporosis therapies, 667–669

Total colectomy, with ileostomy, nephrolithiasis associated with, 980–984
calcium stones, 983–985
etiology, 983–984
treatment, 984
uric acid stones, 980–983
etiology, 980–982
treatment, 982–983

"Trade-off hypothesis," of calcium and phosphorus, in chronic renal failure, 108–109

Trait analysis, quantitative, of gene-environment interactions in type-2 diabetes mellitus, 558–559, 562

Transforming growth factor beta (TGF-β), hypercalcemia and, 145–147, 151

Transplantation. See *specific organ*.

Transplantation experiments, for type 1 diabetes mellitus, 478, 481, 484–485

"Treatment threshold," in evidence-based diagnosis, 579

Triamterene, matrix calculi and, 972

Tricarboxylic acid cycle, citrate as central component of, 886–888

Tricyclic antidepressants, major depression and, 47–48, 51

Triiodothyronine (T3), anorexia nervosa and, 176–177
nonthyroidal illness syndrome and, as treatment, 168
hypothalamic-pituitary-thyroid axis and, 162–163

physiology and tests of, 159–160, 164–165
primary thyroid disease versus, 166–167
reduced concentration of, 160–161, 164
obesity and, 174–176, 185

Tubules, kidney. See *Renal tubules*.

Tumor(s), central diabetes insipidus associated with, 129–130
ectopic, anterior pituitary gland, 199
corticotropin-releasing hormone producing, classification of, 191, 197–199
hypersecretion effects of, 196–197
transcription and processing of, 192–195
endocrine workup on, 205–214
imaging studies of, 214–216
venous sampling of, 214
endocrine versus nonendocrine, 191–192
syndrome of inappropriate antidiuretic hormone secretion associated with, 123–125

Tumor necrosis factor (TNF), hypercalcemia and, 145–149
immunomodulatory vaccination and, 443–444, 447–449
in type 1 diabetes mellitus immunosuppressive therapy, 484–485
neuroendocrine-immune regulatory loop and, 2
sleep disorders and, 26–31

24-Hour urine tests, for ectopic Cushing's syndrome, 205–206
for nephrolithiasis, 1022, 1038–1040
in children, 1007, 1011
primary hyperoxaluric, 935
with small bowel disease, 982–983, 990
for sleep disorders, 19, 21–24, 27, 31

Type-1 diabetes mellitus (T1DM), autoimmune polyendocrine syndrome type I and, characteristics of, 298–299, 391–392
diagnostic approach to, 306, 308
prognosis of, 316–317
treatment of, 311–312
autoimmune polyendocrine syndrome type II and, animal models of, 433–434
autoantibody specifics of, 380
characteristics of, 369–371, 373–375, 391–392
clinical applications of, 382–384
diagnostic approach to, 342–347
genetics of, 355–361
treatment of, 348–350
without Addison's disease, 342
autoimmune polyendocrine syndrome type IV and, animal models of, 435–437
autoimmunity associated with, 278, **391–410**
Addison's disease and, 397–399
celiac disease and, 392–396
congenital rubella syndrome and, 401–402
genetics of, 392–393, 395–397
HLA system in, 275–277
introduction to, 391, 403
juvenile rheumatoid arthritis and, 401
multiple sclerosis and, 400–401
pernicious anemia and, 402–403
polyendocrine syndromes in, 391–392
selective IgA deficiency and, 399–400
self-molecule expression with, 412–413, 419, 421–425
thyroid disease and, 396–397
immunomodulatory vaccination and, 442
immunosuppressive/cytokine therapy for, **477–495**
early prevention attempts, 481–482
glucose control trials, 482
indications for use, 477–479
inhibitable pathologic targets of, 478, 480
introduction to, 477, 491
prevention trials design, 488–490
disease status and progression, 488–489
recruitment protocols, 481, 489–490
prevention trials enrollment, 479–481
recent intervention trials, 482–488
bacillus Calmette-Guerin, 484
cytokines, 479, 484–485
daclizumab, 487–488
immunostimulants, 483–484
immunosuppressives, 479, 485–486
mycophenolate mofetil, 486–487

Type-1 diabetes (*continued*)
nicotinamide, 482–483
vitamin E, 483
untreated hyperglycemia in, 537

Type-2 diabetes mellitus (T2DM), endocrinopathy risks with, 380
gene-environment interaction
etiologies of, **553–566**
environmental factors in, 556
evidence of, 556–557
genetic factors in, 553–556
proven examples of, 559–562
study design as binary state versus continuum, 557–558, 562
study size for detection, 559, 562

U

Ulceration, of diabetic foot. See *Diabetic foot ulceration.*

Ulcerative colitis, nephrolithiasis from, 979, 982
surgery associated with. See *Small bowel resection; Total colectomy.*

Ultrasonic lithotripsy (UL), for percutaneous nephrostolithotomy, 1068–1069

UpToDate, as evidence-based medicine resource, 528
problem-based examples of, 532–533

Urate, analyis for nephrolithiasis, serum, 1010, 1037
analysis for nephrolithiasis, stones, 1040

Urate transporter/channel (UAT), in uric acid excretion, 899–900

Urea, from nitrogen excretion, 897
in childhood nephrolithiasis, 1008

Urease, in urine supersaturation, 858

Urease inhibitors. See *Acetohydroxamic acid.*

Uremic osteodystrophy, mixed, 110–111, 114

Ureteral calculi, surgical management of, 1075–1078
algorithm for, 1075–1076
distal, 1077–1078
mid, 1077
proximal, 1075, 1077

Ureteroscopy (URS), for nephrolithiasis, 1073–1075
hyperuricosuric calcium, 922–923
for urolithiasis, electrohydraulic lithotripsy with, 1071–1072
evolution of, 1071
laser lithotripsy with, 1072

Uric acid excretion, insulin and substrate role in, 901
normal physiology of, 899–900

Uric acid nephrolithiasis, **895–914**
ammonium excretion physiology, 900–901
childhood, 1007–1008
composition analysis of, 1040
diagnosis of, 908–909
from bowel disease, 979–980
ammonium stoenes and, 994–995
small bowel resection and, 994
total colectomy with ileostomy and, 980–983
gout and, 903–904, 908
hyperuricosuric calcium, 915–923
insulin resistance and, 904–908
metabolic syndrome and, 904–908
nitrogen excretion evolution, 896–897
normal excretion of, 899–900
insulin and substrate role, 901
nutritional aspects of, 1026
overview of, 895, 910
pathophysiology of, 901–908
genetic disturbances, 903–904
idiopathic, 904–908
in children, 1002–1003, 1010–1012
schematic depiction of, 905
secondary causes, 901–903, 909
physical chemistry of, 898–899
therapeutic intervention for, 909
with supersaturations, 981–982

Uricase, for hyperuricosuria, 1057–1058

Uricosuric drugs, uric acid nephrolithiasis from, 903

Urinary constituents, with nephrolithiasis, 1031–1033
computer iterative approximation program analysis of, 1038–1040
normal limits of formation and urine variables of, 1041–1042
small bowel resection impact on, 980–982, 985–986, 994–995

Urinary free cortisol (UFC), 24-hour, ectopic Cushing's syndrome and, 205–206

sleep disorders and, 19, 21–24, 27, 31

Urinary iodine excretion, with iodized salt, 683, 691–693

Urine acidification, for cystinuria, 1061
for struvite calculi, 971

Urine albumin concentration (UAC), as evidence-based diagnosis for diabetes, 567–568, 570

Urine albumin excretion rate (UAER), as evidence-based diagnosis for diabetes, 568, 570
sensitivity and specificity of, 570–571

Urine albumin:creatinine ratio (UACR), as evidence-based diagnosis for diabetes, 567–568, 570
likelihood ratios of, 575
predictive value of, 573–574
receiver operating characteristic curve of, 572–573
sensitivity and specificity of, 570–571

Urine alkalinization, for cystinuria, 966
for uric acid nephrolithiasis, 909
in children, 1012
with small bowel disease, 982–983

Urine analysis, cyclical. See *24-Hour urine tests*.
for cystinuria, 960–962
for nephrolithiasis, 1037–1038. See also *Urinary constituents*.
in children, 1010

Urine anion gap, small bowel resection impact on, 995

Urine composition, with nephrolithiasis, 1037–1038

Urine osmolality, arginine vasopressin regulation of, 122–123
systemic disorders impact on, 123–135

Urine supersaturations, urolithiasis and, calcium oxalate stones with, 1020–1023
small bowel resection and, 989–990
physiochemistry of, 855–857
resulting in crystallization, 858–860
uric acid stones with, 981–982
variations in tubular fluid, 861–862

Urine volume, nephrolithiasis and, as preventive measure, 1018–1019
as risk factor, 1051–1052
calcium oxalate in, with bowel disease, 990
calcium pathology in, 869–871
uric acid, 901–903, 909
with bowel disease, 980–981

Urolithiasis. See also *Nephrolithiasis*.
in children. See *Childhood nephrolithiasis*.
physiochemistry of, **855–867**
crystallization as basis of, 855, 858–860
crystallization inside the nephron, 860–861
crystalluria versus stone formation, 862–864
hyperuricosuric calcium, 917–920
solubility and, 855–857
supersaturation and, 855–857
supersaturation resulting in crystallization, 858–860
supersaturation variations in tubular fluid, 861–862
urine supersaturation process, 858
surgical management of, **1065–1082**
open lithotomy, 1072–1073
percutaneous nephrostolithotomy, instrumentation for, 1068–1071
technique evolution, 1068
renal calculi, 1073–1075
shock wave lithotripsy, instrumentation for, 1066–1068
techique evolution, 1065–1066
ureteral calculi, 1075–1078
ureteroscopy, 1071–1072

Utility, of evidence-based diagnosis, 568–570, 579–580
of evidence-based endocrinology, 527
limitations of, 807–810

V

Vaccination(s). See *Immunomodulatory vaccination*.

Validity, of diagnostic test, in evidence-based diagnosis, 568–569
of research. See *Measurement validity*.

Values and value judgments, in evidence-based medicine process, 569, 587, 819, 821, 823–824

Vasopressin, ectopic Cushing's syndrome and, 211–212
stress response and, 174–177

Venous sampling, for ectopic Cushing's syndrome, 214

Ventromedial prefrontal cortex, stress response and, 45, 52

Vertebral fractures, and bone mineral density relationship to postmenopausal osteoporosis therapies, 663–665

Vitamin B12 deficiency, autoimmune polyendocrine syndrome type II and, 380–381
diagnostic approach to, 342–344, 346
treatment of, 349–350
type 1A diabetes mellitus-associated autoimmunity and, 402–403

Vitamin D, as nephrolithiasis factor, genetics of, 871–872, 874–875, 878–879
in childhood, 12, 1003
supersaturation and, 862
chronic renal failure and, 8, 108–110, 113
for autoimmune hypoparathyroidism, 314
hypercalcemia and, 144–145, 148–149, 151, 154
in postmenopausal osteoporosis trials, 661

Vitamin E, in type-1 diabetes mellitus intervention trial, 483

Vitiligo, autoimmune polyendocrine syndrome type I and, 303
autoimmune polyendocrine syndrome type II and, 371, 373, 382
diagnostic approach to, 341, 346

Volume depletion, water homeostasis and, 122

Volume expansion, for cystinuria, 965–966
for hypercalcemia, 152–153

W

Water deprivation test, for central diabetes insipidus, 131

Water homeostasis, **121–140**
arginine vasopressin in, excess secretion effects of, 123–128
insufficient secretion effects of, 128–135
physiology of, 121–123
normal, 121–123
systemic diseases affecting, 123–135

Water intake, nephrolithiasis and, as risk factor, 1018–1019
as treatment, 1051–1052
for primary hyperoxaluric, 936–937
preventive in children, 1012
recommendations on, 1025–1026

Web site(s), for Cochrane Metabolism and Endocrine Disorders Review Group, 616
for evidence-based medicine, 528–531, 807–808, 818
for laboratory screening directory, for genetic disorders, 1012

WebMD, as evidence-based medicine resource, 528–529
problem-based examples of, 532

Weight loss, growth hormone effects of, 178
hypothalamic-pituitary-adrenal effects of, 182–183

Well-being, as evidence-based medicine factor, 615

Western blot analysis, of *AIRE* protein, 323–325

Whitaker syndrome. See *Autoimmune polyglandular syndrome type I (APS I)*.

Work shifts, sleep cycles and, 15

Working capacity, with autoimmune polyglandular syndrome type I, 316

World Health Organization, on iodized salt for iodine deficiency review, 682–683, 685
on osteoporosis and fracture relationship studies, 659, 665

X

Xanthinuria, childhood nephrolithiasis with, 1009

XLAAD syndrome, neonatal, 287–289

X-linked nephrolithiasis, hypercalciuric, 879–880
in childhood, 1004–1006

Xyulose, in oxalate metabolism, 930–931